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        Memory deficits have been reported in patients with chronic HF (heart failure). However, 
little is known about memory performance and the factors that explain memory performance in 
women with HF. The purposes of this study were to (a) examine the memory performance 
among Taiwanese postmenopausal women with heart failure (HF) compared to age- and 
education-matched healthy women, and to determine the factors that explain memory 
performance in women with HF, (b) evaluate the validity of the Chinese version of the CogState 
battery among women with HF in Taiwan, and (c) examine type, frequency, and severity of 
menopausal symptoms in women with HF, compared with healthy participants, and to explore 
the association between menopausal symptoms and memory performance among Taiwanese 
postmenopausal women with HF. 
        A cross-sectional design was used in this study. Seventy-six women with HF and 64 healthy 
women were recruited from one medical center in Taipei, Taiwan. Women completed memory 
tests and measures of demographic variables, menopausal symptoms, HF severity symptoms, and 
global cognitive function. Clinical variables were obtained from medical records. Descriptive 
statistics, comparative statistics, exploratory factor analysis, Pearson product-moment correlation 
coefficients, and multiple regression analyses were used. 
        Women with HF performed significantly worse than healthy women on working and verbal 
memory tests. Among women with HF, older age explained working memory; older age, higher 
HF severity, more comorbidities, and systolic HF explained verbal memory. In addition, the 




onvergent validity. Furthermore, women with HF had worse menopausal symptoms on subscales 
for psychological (anxiety and depressive), somatic, and vasomotor symptoms compared with 
healthy women. Anxiety and sexual symptoms were significantly associated with visual and 
verbal memory performance. In summary, the Chinese CogState Battery is a valid measure of 
memory performance in Taiwanese women with HF. Women with HF had poorer memory 
performance and more severe menopausal symptoms compared with healthy women.  Nurses 
and health care professionals should assist women with HF by early assessment and 
recommendations regarding compensation for memory deficits. Interventions tailored to these 
identified factors can be developed to improve memory performance for Taiwanese 
postmenopausal women with HF. 
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        Heart failure (HF) affects 6.6 million people, with 670,000 new cases diagnosed annually in 
the United States (Roger et al., 2012). The prevalence of HF rises with increasing age due to 
long-standing cardiovascular abnormalities. The most common causes of HF include coronary 
artery disease, hypertension, and valvular heart disease. The affected heart is unable to pump 
vigorously enough to support the needs of the body (Brozena & Jessup, 2003). In particular, the 
brain is a critical organ that requires oxygen to function (Lezak, 2004). Moreover, as cardiac 
output continues to decline, the neurohormonal counter-regulatory response to HF leads to 
deterioration of cardiac function and a decrease in the autoregulation mechanisms and may 
increase vascular resistance, which contributes to the reduction of cardiac output to the brain 
(Choi et al., 2006; Gruhn et al., 2001; Sila, 2007). Heart failure is, however, a chronic condition 
in which the body has time to activate compensatory mechanisms for improving cardiac 
performance (Davis, 2002). 
        Cognitive deficits, including memory changes, resulting from cardiovascular diseases are a 
matter of increasing interest. Memory is a set of functional systems that is supported by distinct 
and interrelated regions of the brain. Research has indicated that there are neurobiological 
changes and brain abnormalities that occur in the hippocampus in HF, which may affect memory 
functioning (Gruhn et al., 2001; Kumar et al., 2009; Vogels, & Flier, et al., 2007; Vogels, 
Oosterman, van Harten, & Gouw, et al., 2007). Evidence supports the biological hypothesis that 




shows deficits in working memory and episodic long-term memory (Hawkins et al., 2012; 
Kindermann et al., 2012; Pressler et al., 2010; Sauvé, Lewis, Blankenbiller, Rickabaugh, & 
Pressler, 2009; Vogels, Oosterman, van Harten, Scheltens, van der Flier, Schroeder-Tanka, et al., 
2007). Importantly, cognitive deficits in patients with HF have been found to be associated with 
disability, decreased quality of life, increased frequency of hospital readmissions, and mortality 
(Sila, 2007).  
        Recent review of the literature demonstrated a prevalence rate of cognitive deficits ranging 
from 25%-50% in patients with chronic HF (Pressler et al., 2010;  Sauvé et al., 2009; Vogels, 
Oosterman, van Harten, Scheltens, et al., 2007). In a study conducted to explore hypotension and 
cognitive impairment, women with HF (n=836) had an increased probability of cognitive 
impairment compared to men (n=747), as assessed by the Hodkinson Mental Test (Zuccala et al., 
2001). Altimir et al. (2005) evaluated 360 HF patients (27.5% women) using the Pfeiffer Test 
and found more frequent abnormal cognitive testing scores in women than men (15.2 % vs. 5 %, 
p = 0.003). Bennett, Baker and Huster (1998) used a self-report measure of cognitive function 
among 30 women with HF and found that cognitive deficits were a problem for over one third of 
them. Moreover, female gender was associated with poorer memory performance on the tasks of 
attention, early recall, and delayed recall (Sauvé et al., 2009). 
        Approximately 46% of HF cases are estimated to be women (Roger, et al., 2012). Women 
with HF exhibit more physiological and psychological symptoms than men but are less likely to 
be referred for treatment and clinical trials (Frazier et al., 2007; Stromberg & Martensson, 2003). 
Moreover, women with HF experience more hospital discharges and have longer hospitalizations 




involving HF has been studied predominantly in men, with results generalized to women. 
Women have been under-represented in cardiovascular research (Klabnik & Murin, 2012). 
        Of women diagnosed with HF, 70% are older than 50, the average age of menopause 
(Schocken, Arrieta, Leaverton, & Rosse, 1992; Roger et al., 2012). Some studies have 
demonstrated that estrogen acts as a neuroprotector in maintaining cognitive function among 
healthy elderly women (Lebrun et al., 2005; Heys et al., 2012), perhaps related to the fact that 
there are multiple sites of estrogen receptors in the brain, including the hippocampus (the main 
structure for memory) (Ancelin & Ritchie, 2005). With their current life expectancy, women are 
more likely to live one third of their lives in the postmenopausal stage, a state of relative estrogen 
deficiency (Lebrun et al., 2005). The possible acceleration of memory decline in postmenopausal 
women with HF may lead to difficulties in regard to maintenance of functional ability for 
successful living. However, despite the importance of estrogen in maintaining cognitive function, 
results from studies of cognition and HF have failed to provide information about memory 
performance in postmenopausal women.  
        Overall, almost all studies of memory function in the HF population have combined results 
for men and women (Hawkins et al., 2012; Kindermann et al., 2012; Pressler et al., 2010; 
Pressler et al., 2011; Sauvé et al, 2009; Vogels, Oosterman, van Harten, Scheltens, et al., 2007), 
thus, we know little about gender specific differences. Only one study addressed women with 
memory deficits, using self-report methods (Bennett et al., 1998). Importantly, no studies were 
found that investigated the association between menopausal symptoms related with estrogen 
decline and memory function. Although memory function in HF has been studied in the western 
countries, no data were available for Asian countries, including Taiwan.  




        Evidence suggests that HF has an adverse effect on memory performance and the 
neurobiological changes and brain abnormalities that appear in areas involved in memory 
function (Vogels, Oosterman, van Harten, & Gouw, et al., 2007; Woo et al., 2009).  To our 
knowledge, no published studies have explored the nature of memory performance and related 
factors among women with HF. Although literature suggests estrogen influences memory 
function (Luine & Frankfurt, 2010; Heys et al., 2011), no study has been identified that examines 
menopausal symptoms associated with estrogen decline in relation to memory performance in 
women with HF. Furthermore, little is known about the nature of memory performance among 
postmenopausal Taiwanese women with HF. One reason is likely due to lack of the valid 
psychometric instruments for detecting memory decline in Chinese-speaking populations such as 
Taiwan.  
Structure of the Dissertation 
        This is a three-manuscript format dissertation. The chapters include the introduction, three 
manuscript-style papers, and a conclusion. The first chapter provides a brief background, 
statement of the problem, and theoretical perspectives. Chapter 2 presents the first paper which 
examines memory performance in Taiwanese postmenopausal women with HF and possible 
influencing factors. Chapter 3 is the second paper, which examines validity of the Chinese 
Version of the CogState computerized cognitive assessment battery. Chapter 4 is the third paper, 
which addresses results for menopausal symptoms and their relationships to memory 
performance among Taiwanese postmenopausal women with HF. Chapter 5, the final chapter, 
presents a summary of the findings, strengths, weaknesses, limitations, and implications of the 





The theoretical perspectives for the study link the neurobiological theory of heart failure, the 
biological theory of menopausal-related estrogen loss in post-menopausal women, and the 
neurobiological theory of estrogen to the neurobehavioral theory for memory functioning, 
specifically working memory and episodic memory. 
Memory Functioning 
        Memory, a critical aspect of cognition, is the way the human brain processes information 
for later usage (Budson, 2009), or the mental ability to encode, store, and retrieve information 
(Sherwin & Henry, 2008). These processes ensure that knowledge is gained and recalled for use 
in our environment. Memory is necessary for high level cognitive functions such as language 
processing, visuospatial thinking, reasoning, problem solving, and decision making (Kandel, 
Kupfermann, & Iversen, 2000). Human memory consists of several functional systems that 
contribute to the encoding, storing, and retrieving of information (Giovanello & Verfaellie, 
2001). A major aspect of memory relates to duration of retained information, such as working 
memory or short-term memory and long-term memory (Giovanello & Verfaellie, 2001). Memory 
can additionally be categorized by the material sources to be remembered, such as verbal or 
visual memories (Brewer, Zhao, Desmond, Glover, & Gabrieli, 1998). For example, verbal 
memory refers to memory for words and verbal items. It is the ability related to use of words, 
such as recall of words or materials that can be mediated verbally (Kimura, 1999). 
        Working memory refers to the cognitive ability to temporarily store and manipulate limited 
amounts of information for use in guiding behavior (Baddeley, 2000). The characteristics of 
working memory are applicable to more complex mental tasks that maintain information in the 
service of ongoing cognitive activities (Baddeley, 2000). According to Baddeley and Hitch 




systems. The central executive system is a control system of limited attentional capacity that is 
responsible for manipulating information and coordinating information flow to and from short-
term memory systems (Repov & Baddeley 2006). The short-term storage systems store and 
maintain different types of information (phonological and spatial). The core working memory 
system is prefrontal cortex (Budson, 2009). The rate of decline of working memory has been 
shown to be equivalent decade by decade (Park et al., 2002 ); deficits for working memory 
among individuals at age 70 and older are greater than for other ages in both verbal and 
visuospatial memory (Conner, 2001). Impairment of working memory may present in different 
ways. For example, because attention control has the ability to inhibit irrelevant information, 
decreased attentional capacity may lead to cognitive and behavioral manifestations such as 
distractibility, impulsivity, and irritability (Chiu, 2002). Patients with impaired working memory 
show an inability to pay attention, which leads to the problem of holding new or modified 
information for short-term, which cannot later be encoded into episodic long-term memory 
(Budson, 2009; Fletcher & Henson, 2001). 
        Episodic memory is a declarative long-term memory system for personally experienced 
events (Budson, 2009; Tulving, 2002). Episodic memory processes include the encoding, storage, 
and retrieval processes that mediate different forms of memory (Mayes & Roberts, 2001). The 
process of storing information as long-term memory, or consolidation, is the processing of 
encoded information from hippocampal and medial temporal lobes to the neocortex for long-
term memory storage (Lezak, 2004). The episodic memory system is dependent on the medial 
temporal lobes, including the hippocampus. Other structures involved in episodic memory are 
the prefrontal cortex, the fornix, the mammillary body, and the anterior thalamus nucleus 




decline accelerates significantly over 50 years of age (Verhaeghen & Salthouse, 1997). Memory 
declines associated with aging are found in encoding and retrieving of information; storage of 
information is least affected (Price, Said, & Haaland, 2004).  
Neural Processes in Heart Failure and their Effect on Memory 
        Although the causes for heart failure that result in neurobiological change that may 
contribute to memory deficits are not known, factors that might be associated include decreased 
cerebral blood flow leading to deprivation of oxygen and glucose supply, or to metabolic 
disturbances and HF-related cerebral embolism (Alves & Busatto, 2006). There is evidence of 
neurological change including neurobiological damage, cerebral circulation reduction, and brain 
abnormalities in relation to cerebral hypoperfusion in animal models and heart failure patients; 
some studies also included memory function measures and are described in the following section. 
         Neurobiological damage in chronic cerebral hypoperfusion.  Given that HF is 
accompanied by reduced cerebral blood flow, animal models showing chronic cerebral 
hypoperfusion have been applied to humans to examine neuropathologic changes in the 
hippocampus, one of the brain regions most sensitive to decreased oxygenation (Farkas et al., 
2007). Neurobiological damage includes loss of neurons and reduction of dendritic arborizations 
and synaptic contacts and is hypothesized to be related to spatial learning and memory (Bennett, 
Tenniswood, Chen, Davidson, & Keyes, 1998; Liu, Zhang, Zheng, & Zhang, 2005). Moreover, 
some studies in animals have reported that the severity and extent of brain damage depend on the 
degree and duration of hypoperfusion (Farkas et al., 2007; Kaplan et al., 1991). 
        Cerebral circulation reduction in heart failure.  Studies investigating HF influences on 
cerebral circulation and glucose metabolism have been established. Global and regional cerebral 




al., 2008). Some evidence showed that decreased cerebral blood flow was related to cognitive 
deficits in HF patients (Alves et al., 2005; Jesus et al., 2006). 
        Brain abnormalities in heart failure.  Studies have reported structural brain abnormalities 
such as brain atrophy and volume loss in HF patients, as assessed by use of magnetic resonance 
imaging (MRI). Heart failure patients showed significant medial temporal lobe atrophy as 
compared to other cardiac patients and healthy controls (Vogels, Flier, et al., 2007). The medial 
temporal lobe atrophy was significantly negatively correlated with memory (Vogels, Oosterman, 
van Harten, & Gouw, et al., 2007). Reduced gray matter in the brain presented in areas related to 
short-term memory and learning, such as the hippocampus and hippocampus output fibers that 
project to the anterior thalamus, caudate nuclei, anterior fornix, and corpus callosum in HF 
patients (Woo et al., 2009). A past study found that mammillary body volumes and cross-
sectional fornix areas fibers (which are essential to the route signals between areas integrating 
memory formation) were significantly reduced in HF (Kumar et al., 2009).          
Menopause 
            Menopause is characterized by the cessation of menstruation for twelve months or more; 
the average age of menopause is 51 years old. Sex hormone levels, such as those for estrogen 
and progesterone, are reduced because of decreased ovarian activity after menopause (Lokken & 
Ferraro, 2006). Although ovarian production of estrogen ceases after menopause, 
postmenopausal women continue to register detectable concentrations of circulating estrogen. 
Estrogen (estrodiol, E2) is primarily produced by aromatization of testosterone and reduction of 
estrone (E1), in turn arises through aromatization of androstenedione in peripheral adipose tissue 
(Judd, Shamonki, Frumar, & Lagasse, 1982; McTiernan et al., 2008). Estradiol levels rise and 




110 pg/ml (Berga, 2002). After menopause, estrogen levels drop markedly and frequently are 
below the detection limits of the assay (Al-Azzawi & Palacios, 2009). By three years after 
postmenopausal decline, estrogen levels attain relative stability to the normal postmenopausal 
values of 13.3 pg/ml (SD=24.7 pg/ml). Several factors are associated with estrogen 
concentrations. For example, postmenopausal women with increased body mass index (BMI) 
show higher levels of serum estradiol and estrone (Rannevik et al., 1995). One study found that 
the passage of time after menopause was negatively associated with estradiol concentrations 
(Chubak et al., 2004).  
        Menopausal symptoms are those that directly result from estrogen decrease as women go 
through menopausal stages (Rahman, Zainudin, & Mun, 2010). Symptoms can be grouped into 
vasomotor symptoms such as hot flushes (also referred to as hot flashes) and night sweats, 
physical symptoms (dizziness tightness in head or body, parts of body feeling numb, headaches, 
muscle and joint pains, loss of feeling in hands or feet, and breathing difficulties), psychological 
symptoms (anxiety and depression) and sexual complaints (loss of interest in sex) (Greene, 1998). 
Symptoms in women at the post-menopause stage are variable due to diverse biological and 
psychosocial factors. Estrogen decline is the most important factor that might explain the 
symptom differences (Malacara, Prez-Luque, Martnez-Garza, & Snchez-Marn, 2004).          
        Studies indicated that symptom severity correlates with estrogen changes. In longitudinal 
studies of the menopausal transition in early postmenopausal women, low estrone levels (highly 
correlated with serum estradiol levels) have been associated with higher hot flash severity and 
decreased sexual desire (Woods, Mitchell, & Smith-Dijulio, 2010;  Woods, Smith-Dijulio, Tao, 
& Mitchell, 2007).  Moreover, a study of 88 symptomatic menopausal women showed relief 




symptoms after using hormone therapy (HT) (Akhila & Pratapkumar, 2006). Other studies also 
reported that HT was associated with significant improvements in hot flushes, and quality-of-life 
scores in symptomatic postmenopausal women (Lobo et al., 2009; Pinkerton, Pickar, Racketa, & 
Mirkin, 2012). 
Neurobiological Effects of Estrogen on Memory 
        Estrogen in the central nervous system.  Estrogen potentially affects cognitive function by 
means of mechanisms that influence the structure and function of the brain. There are two types 
of estrogen receptors, ER-α and ER-β, localized in the hypothalamus, hippocampus, cerebral 
cortex, midbrain, and brainstem (Sherwin & Henry, 2008). Estrogen acts on the central nervous 
system by modulating the synthesis, release, and metabolism of neurotransmitters and 
neuropeptides. It also exerts effects on neuron excitability, morphological structure, and synaptic 
functionings through plasma membrane-associated estrogen receptors (Genazzani, Pluchino, 
Luisi, & Luisi, 2007). Estrogen additionally affects neurotransmitters such as in the serotonergic, 
cholinergic, dopaminergic, and nonadrenergic systems that can contribute to numerous cognitive 
functions (McEwen, 2002). Moreover, estrogen exerts neurotrophic effects because estrogen-
binding sites co-localize and facilitate neurotrophins such as the brain-derived neurotrophic 
factor (BDNF) (Scharfman & Maclusky, 2005). Estrogen may also have neuroprotective effects 
in reducing cell apoptosis (Nilsen, Mor, & Naftolin, 2000) and modulating neuronal growth and 
synaptic plasticity (Woolley & McEwen, 1998). 
        Estrogen reflected brain areas and domains.  Post-mortem studies in brain areas have 
shown that estradiol concentrations were significantly higher in brains of fertile women as 
compared to postmenopausal women, which indicates that peripheral serum levels of estradiol 




functional plasticity in the adult hippocampus in animal models (Woolley, 1998). Studies have 
found that estrogen treatment increased dendritic spine density on CA1 pyramidal neurons in the 
hippocampus (Gould, Woolley, Frankfurt, & McEwen, 1990) as well as enhancing N-methyl-D-
aspartate (NMDA) receptors binding in the CA1, which related to increased dendritic spine 
density and sensitivity in CA1(Cyr et al., 2001). Finally, hippocampus-dependent cognitive 
function may be affected, such as in memory and learning (Sherwin & Henry, 2008).  
        In summary, theoretical perspectives suggest that HF and estrogen decline after menopause 
may influence memory performance-associated areas of the brain, including the hippocampus. 
Postmenopausal women with HF may have poorer working memory and episodic memory 
(verbal memory, and visual memory) compared to healthy postmenopausal women. Age, HF 
severity, and postmenopausal symptoms associated with estrogen decline that may affect 
memory performance are hypothesized to explain working memory and episodic memory 
deficits among postmenopausal women with HF. To understand memory performance and 
possible influencing factors in postmenopausal women with HF, this study provides a scientific 
basis to explore mechanisms of memory performance and develop effective nursing 
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Memory Performance among Taiwanese Postmenopausal Women with Heart Failure 
Abstract 
Background: There are limited data describing the nature of memory deficits in women with HF.  
Objectives: The aims of this study were to examine the memory performance among Taiwanese 
postmenopausal women with HF compared to age- and education-matched healthy women, and 
to determine the factors that explain memory performance in women with HF.  
Methods and Results: Seventy-six women with HF and 64 healthy women were recruited from 
Taiwan. Women completed memory tests; measures of the postmenopausal symptoms associated 
with estrogen decline and HF severity were collected. Women with HF performed significantly 
worse than healthy women on tests of working memory and verbal memory. Among women 
with HF, older age explained poorer working memory; older age, higher HF severity, more 
comorbidities, and systolic HF explained worse verbal memory.  
Conclusion: The study provides important insights into poor memory performance in Taiwanese 
postmenopausal women with HF and significant factors associated with performance. 
Interventions focusing on those factors should be tested to prevent memory loss in women in HF. 
Key words: Heart failure, Memory, Postmenopausal, Women 
 






          Heart failure (HF) affects more than 6.6 million adults in the United States.
1
  Of  patients 
with heart failure, approximately 46% are estimated to be women, and at least 70% of those 
women are above 50 years of age.
1,2
  Although women with HF have been less studied than 
men,
3
  they have reported worse physiological and psychological symptoms,
4,5
  more hospital 
discharges
1
  and longer hospitalizations than men, leading to increased costs for HF care.
4, 6
        
         Cognitive deficits have been reported in patients with HF.
7, 8
  Patients with HF have more 
than a 4-fold increased risk for development of cognitive impairment compared to persons 
without HF.
9
  According to past studies, the prevalence of cognitive dysfunction is estimated to 
be 25% to 50% among the HF population.
7,9,10
  The most frequently affected cognitive domain 
found in HF patients is memory.
11
  Past studies have indicated that HF patients experienced 
impaired working memory, verbal memory and visual memory.
12-15
 Memory deficits in HF 
patients indicate difficulties in learning, storing, and retrieving new information. Individuals with 
decreased memory function are unable to effectively function in daily life, are more likely to 
have difficulties in learning, retaining, and recalling information in understanding and 




        Almost all studies of cognitive deficits in the HF population have included samples with 
more men than women, and few studies have reported cognitive results separately for women 
with HF.  In a study that included 1583 hospitalized patients with HF, investigators assessed 
cognitive impairment using the Hodkinson Abbreviated Mental Test. The results indicated that 
being female and having HF (n=836) was associated with an increased probability of cognitive 
impairment.
16 




Test; 360 patients (mean age 65.2 years, 41.7% ≥70 years, 27.5% women) were evaluated. 
Scores on the Pfeiffer Test were abnormal in 7.8% of patients, and an abnormal score was more 
frequent in older patients (14% vs. 3.3%, p <0.001) and in women (15.2% vs. 5%, p = 0.003). 
17  
Bennett, Baker, and Huster
18  
used a self-report measure of cognitive impairment, the Alertness 
Behavior Scale (ABS) of the Sickness Impact Profile, among 30 women with HF. The ABS 
describes problems patients experience in memory, attention and concentration.  Over one third 
of the women reported that cognitive deficits were a problem. However, the above studies used a 
screening or self-report questionnaire to assess cognitive function, rather than using valid 
neuropsychological tests. Moreover, study participant groups were selective:  two of the studies 
included only elderly patients and two studies recruited hospitalized patients. There are little data 
on memory function in the population of women with HF.  
           Although the underlying mechanism for memory loss in HF remains unclear, the most 
widely accepted potential etiologies are brain injury from multiple cerebral emboli and decreased 
cerebral blood flow caused by low cardiac output, leading to impaired cerebral autoregulation, 
cerebral hypoperfusion, and deprivation of oxygen to the brain. 
19-23
   Studies have suggested that 
global cerebral blood flow was reduced in HF patients. Gruhn et al. 
21 
documented that global 
cerebral blood flow measured by single photon emission computed tomography was significantly 
reduced by 31% in patients with New York Heart Association (NYHA) functional Class III and 
IV(n=12) compared to a healthy group (n=12). Choi et al. 
24 
found that global cerebral blood 
flow was 19% less in HF patients (n=52) than in age-matched healthy participants (n=10). 
Global cerebral blood flow was related to severity of HF measured by NYHA functional class, 
serum B-type natriuretic peptide level and duration of HF.  Some evidence showed that 






significant reductions of cerebral blood flow in HF patients compared to age-matched elderly 
healthy control participants. The degree of cognitive deficits, assessed by the Cambridge Mental 
Disorders of the Elderly Examination (CAMCOG), was correlated with cerebral blood flow in 
the posterior cingulate cortex and precuneus (areas involved in tasks including episodic memory 
retrieval, spatial orientation and memory). Jesus et al. 
26  
also reported that decreased cerebral 
blood flow velocity in the right middle cerebral artery was significantly related to lower Mini-
Mental Status Examination (MMSE) score in patients with HF (n=83)(r = 0.231 p = 0.039). 
        Evidence from animal models suggests that inadequate cerebral perfusion and cerebral 
hypoxia result in neuronal damage and loss of dendritic structure and synaptic contacts in the 
hippocampus that may prove to be one of the mechanisms of memory impairment. 
27 
The 
hippocampus is one of the regions of the brain most vulnerable to reduced blood flow. 
28  
The 
hippocampus, located within the medial temporal lobe, is essential in the acquisition of new 
information, and consolidating items from short-term to long-term memory. Conjecturally, then, 
the damage in affected brain areas such as the hippocampus may lead to learning difficulties and 
short-term and long-term memory problems. 
        Studies using magnetic resonance imaging (MRI) support that structural changes such as 
brain atrophy and volume loss appear in areas involved in memory loss. Schmidt et al. 
29 
demonstrated that HF patients with a significantly higher rate of cortical and ventricular atrophy 
performed worse on verbal memory and learning, and vigilance tests. Vogels et al. 
30 
identified 
more medial temporal lobe atrophy in HF patients (n=58) as compared to healthy control 
participants (n=42). In their further study, 
31
 the investigators also found medial temporal lobe 
atrophy to be significantly and negatively correlated with memory. Brain volume loss was 
demonstrated in HF patients. Woo et al. 
32 




related to short-term memory and learning, including the hippocampus and hippocampus output 
fibers that project to the anterior thalamus, caudate nuclei, anterior fornix, and corpus callosum 
in HF patients (n=13) compared to age-matched healthy control participants (n=49). Additionally, 
women with HF (n=5) had more injured areas, although the sample was small. Moreover, Kumar 
et al. 
33 
found that mammillary body volumes and cross-sectional fornix areas were significantly 
reduced in HF patients (n=17) as compared to control participants (n=50). The authors suggested 
that the injured mammillary body and fornix fibers may contribute to impaired spatial and 
working memory because of their important roles to memory processing.  
        Some evidence revealed that memory performance decreases with increasing age in HF. 
13, 
34, 35  
 Others reported that years of education are positively related to memory function. 
13, 36 
Multiple comorbidities are common in patients with HF and their combined etiology has been 
related to deficits in verbal learning. 
13 
One study demonstrated that some chronic conditions 
such as hypertension are independent predictors of cognitive impairment. 
37  
Increased severity of 
HF has been related to more deficits in verbal 
13, 37, 38  
and working memory.
 37 
 Almost all studies 
of memory function in the HF population have combined men and women; thus, we know little 
about gender-specific factors that may influence memory in women with HF.  
        The relationship between memory deficits and their contributing factors has not been 
examined fully in women with HF.  One factor that may be related to memory function in 
women with HF is estrogen level. Estrogen potentially affects cognitive function by means of 
mechanisms that influence the structure and function of the brain. The hippocampus, one of the 
brain areas with many estrogen receptors, is known to be the main structure for memory. 
 39, 40 
Studies have shown that endogenous estrogen has a positive association with verbal memory in 
healthy postmenopausal women. 
41-43  






 no studies were found in the literature that have examined menopausal 
symptoms or effects of estrogen decline after menopause, such as menopausal status, use of 
hormone replacement therapy, 
14  
and duration of menopause, that may contribute to memory 
deficits in women with HF.  
        In summary, although nearly half of the patients with HF are women, most studies of 
cognitive function in HF patients have combined men and women. There are limited data 
describing the nature of memory deficits in women with HF. In addition, no studies were found 
that considered the gender-specific factors that may influence memory function and examined 
memory performance in a sample of women with HF who were postmenopausal. Therefore, the 
primary aim of this study was to examine memory performance among Taiwanese 
postmenopausal women with HF compared with age- and education-matched healthy control 
participants. The secondary aim was to evaluate factors that explain memory performance among 
women with HF. Hypotheses were (1) Taiwanese postmenopausal women with HF have poorer 
working memory, verbal memory, and visual memory performance in comparison with age- and 
education-matched healthy women participants and (2) age, HF severity, and postmenopausal 
symptoms associated with estrogen decline explain working memory, verbal memory, and visual 
memory performance among Taiwanese postmenopausal women with HF. 
Method 
Design and Procedures 
        This cross-sectional study used a convenience sample. Approvals for protection of human 
subjects were obtained from the University of Michigan, Health Science Human Subject Review 




Taiwan. Patients were recruited from the Tri-Service General Hospital from November 2010 to 
October 2011.   
         After obtaining written informed consent, a registered nurse with neuropsychological 
assessment training collected the data. Participation included face-to-face interviews for both HF 
and non-HF groups and medical records review for the HF group. The interviews took place in 
private rooms at hospital outpatient clinics. Baseline data including demographic and clinical 
information, postmenopausal symptoms associated with estrogen decline, HF severity, and 
global cognitive function were collected by the investigator using questionnaires. After 
completing questionnaires, the investigator explained and administered computerized 
neuropsychological tests with a laptop computer. Participants were not required to have prior 
computer experience to take the computerized tests. The administration time of the interview was 
about 60 to 90 minutes. To ensure a quiet environment with minimal distractions, the participants 
used noise cancelling headphones to minimize distraction noise. Participants were requested to 
turn off their cell phones and their family and friends were required to wait outside the room 
during the neuropsychological tests. There was a sign on the door that read “Testing- Please Do 
Not Disturb”. Participants were paid $10 (NT300) in the form of a gift card for participating in 
the entire interview session. The investigator abstracted data about HF conditions from medical 
records using a structured checklist.  
Sample 
        Seventy-six women with chronic HF were recruited from cardiovascular clinics and 64 age- 
and education- matched healthy women were recruited from among outpatients of the 
gynecology clinic, the women’s health center, and volunteers in the same hospital. Eligibility 




postmenopausal based on the women's self-report and last menstrual cycle having been 
completed more than 12 months earlier; and  4) having a documented diagnosis of HF of 
duration at least 6 months. Women were excluded if they had one of the following conditions 
that may cause cognitive deficits: 1) a documented history of neurological disease or condition 
(such as stroke, Alzheimer’s disease, epilepsy, head injury with loss of consciousness longer than 
30 minutes, dementia, or Parkinson’s disease); 2) history of recurrent mental disorders diagnosis 
or undergoing treatment with psychotropic medication; 3) history of drug/ alcohol abuse; 4) renal 
failure requiring hemodialysis and terminal cancer; 5) diagnosed encephalopathy; and 6) 
impaired sensory problems such as hearing loss and visual problems. 
For age- and education- matched healthy women, eligibility criteria were: 1) age 50 years 
and older; 2) fluent in Mandarin; 3) naturally postmenopausal, as above; and 4) no major medical 
condition. Women who had cardiovascular risk factors controlled by medication (such as 
hypertension with blood pressure less than 140/90 mmHg or hyperlipidemia with cholesterol less 
than 200 mg/dl) were eligible for the healthy group. Women were excluded if they met any of 
the exclusion criteria described for the HF group. 
Measures 
        Demographic and clinical data included personal information (age, race, education, marital 
status, employment status, and blood pressure) and menopausal history (age when menstruation 
began, number of pregnancies, number of live births, age at menopause, duration of menopause, 
hysterectomy and ovarectomy, and estrogen replacement therapy) that were obtained at interview. 
The number of comorbidities and HF condition such as left ventricular ejection fraction (LVEF), 
New York Heart Association (NYHA) class, heart failure duration, and type of HF) were also 




        The Montreal Cognitive Assessment (MoCA) was used to measure global cognitive 
function. 
45 
The MoCA is a one-page 30-point test that takes 10 minutes to administer. It has 
eight subscores: visuospatial abilities (5 points); naming (3 points); short-term memory recall 
task (5 points); attention task (6 points); language (3 points); verbal abstraction task (2 points); 
memory (0 points); and orientation (6 points). One point is added if the participant has less than 
12 years of education. The total score of the MoCA ranges from 0 to 30, with higher scores 
indicating better global cognitive function. The MoCA is a test with high sensitivity (90%) and 
specificity (87%) for detecting possible mild cognitive impairment (MCI). 
45 
Using the cutoff 
score of 23/24 to detect possible MCI, the Chinese version of the MoCA had an excellent 
sensitivity of 92% and specificity of 78% to detect possible MCI. 
46   
The criterion validity, 
internal consistency and test-retest reliability were satisfactory in the Chinese version of MoCA 
among 40 Chinese patients with cerebral small vessel disease and 40 matched controls. 
47  
 
       Menopausal symptoms have been associated with estrogen levels. 
44 
The Greene Climacteric 
Scale (GCS) was used to measure postmenopausal symptoms associated with estrogen decline. 
The 21 items in the questionnaire reflect symptom groups for women during different 
menopausal stages:  2 items for vasomotor
 
symptoms (hot flushes and night sweats); 11 items for 
psychological
 
symptoms (anxiety and depression); 7 items for somatic symptoms (physical); and 
1 item for loss of interest in sex (libido). 
48  
Each item is rated by participants according to its 
severity using a four-point scale as “not at all” (0), “a little” (1), “quite a bit” (2), and 'extremely” 
(3). Factor analyses have established construct validity of the 21 symptom items. 
48
 Test-retest 
correlations range from 0.82-0.94 among menopausal women. 
49 
The Chinese version of the GCS 
has been used in postmenopausal women with satisfactory construct validity and reliability 
(Cronbach’s α=0.93). 
50, 51 




women were added to the questionnaire: cold sweats (night or day), waking up during the night, 
vaginal dryness, backache, and forgetfulness. 
52, 53 
 The total score of the questionnaire is the sum 
of the 26 items, ranging from 0 to 78. Higher scores indicate more symptoms or more severe 
symptoms. In this sample, the Cronbach’s alpha was 0.90.  
       The NYHA functional classification and the Duke Activity Status Index (DASI) were used 
as two measures of perceived functional capacity to evaluate severity of HF symptoms. 
54 





 Validity and reliability of the NYHA classes have been reported. 
56
 
The DASI is a 12-item questionnaire with 4-point response scales that measures perceived 
functional capacity and correlates well with peak oxygen uptake. This instrument is based on a 
patient's ability to perform common activities of daily living. 
57 
The activities in the 
questionnaire include personal care, ambulation, household tasks, sexual function, and recreation. 
58 
Each item is weighted by metabolic cost, and
 
the total score is calculated by multiplying the 
weights of the 12 items. Possible scores range from 0 to 58.2. Higher scores represent better 
perceived functional capacity. The Cronbach's α reliability coefficient for DASI scores was high 
(0.87) in a chronic HF population. 
59 
This questionnaire has been validated in the Chinese 
language. 
60 
In the present sample, the Cronbach’s alpha was 0.69.  
        Six tasks from the CogState neuropsychological test battery were administered to measure 
memory performance and other cognitive abilities. Reviews of each test have been described in 
detail. 
61, 62, 63 
 Although the primary outcomes of the study relate to memory performance, we 
also included measures of psychomotor speed (Detection task, DET) and attention (Identification 
Task, IDN).  On the CogState tests, each task had an instructional part and a scored part 




speed by measuring speed of performance. Participants respond to the face-up card as soon as 
possible in the task. The Identification Task assesses working memory by measuring speed of 
performance. Participants are asked to press different keys as soon as possible if the card that 
appears in the center of the computer screen is red or black. 
64
 A lower score for performance 
speed indicated better performance. 
       Working memory refers to the cognitive ability to temporarily store and manipulate limited 
amounts of information for use in guiding behavior. 
65 
Working memory was measured by the 
One Back Task (OBK). The OBK assesses working memory by measuring accuracy of 
performance. The participant responds according to whether the new card is the same as or 
different from the previously presented card. 
66   
Higher score indicates better working memory 
performance. 
 
        Verbal memory refers to memory for words and verbal items. It is the ability related to use 
of words, such as recall of words or materials that can be mediated verbally. 
67 
Verbal memory 
was measured by the International Shopping List Task (ISLT). The International Shopping List 
Task is the verbal memory task that consists of immediate free recall for a series of 12-word lists 
for three trials, followed by recall of the word list after a 20-minute delay. The scores of the 
ISLT are the total number of words correctly recalled in the sum of trials 1 to 3 and the correct 
number of recalled words after a 20-minute delay. The range of correct scores is 0-36 in ISLT 
and the range of correct scores is 0-12 in ISLT-DR (Delayed Recall). A higher score indicates 
better verbal memory performance. 
 
        
Visual memory refers to the ability to explicitly remember visual episodic information that 
was seen previously.
68  
This was measured by the One Card Learning Task (OCL) and the 




visual memory by measuring accuracy of performance. The participants respond using different 
keys depending upon whether the face-up card has appeared before or not. 
61  
A higher accuracy 
score indicated better performance. In the Continuous Paired Associate Learning Task, the 
participants were required to remember the pictures hidden beneath the peripheral location on the 
screen first, and asked to determine whether a single picture presented in the center of the screen 
was the same as any one of the peripheral pictures and tap the same one in the peripheral location. 
69 
It is scored as the total number of errors across five rounds, with a lower score reflecting better 
visual memory performance.
 
        Tasks were selected from the CogState Battery because of their brevity, good usability, 
61
 
and demonstrated validity and reliability that has sensitivity for detection of decline over time in 
older adults.  
62,63  
All tasks in the Chinese version were translated using a linguistically validated 
process to produce an instrument that is conceptually equivalent to the English version. The 
validation process included seven steps: conceptual definition, forward translation, backward 
translation, pilot testing, international harmonization, proofreading, and report. 
70 
The method for 
using the Chinese version of the CogState is the same as English version. It is easy to administer 
and scoring is completed within the program. The battery requires approximately 20 minutes for 
completion.
 
For these CogState tests, the score of a speed test was computed as the mean log10 
transformed reaction time for correct response and the score of an accuracy test was computed as 
the arcsine transformation of the proportion of the correct response. Transformations were 
applied to normalize the distribution.  
Statistical analyses 
        Descriptive statistics such as mean, medians, standard deviation, and percentages were used 




healthy groups were compared using independent t-tests, chi-square tests, or Fisher’exact tests. 
Cronbach’s alpha was calculated to estimate internal consistency reliability for the GCS and the 
DASI. For hypothesis one, analysis of covariance (ANCOVA) was used for each test of memory 
performance to evaluate differences in means adjusting for age and education between the HF 
group and the healthy comparison group. Each subtest of the CogState battery was standardized 
by creating z scores whereby the healthy control mean was set to zero and the standard deviation 
set to one. 
71, 72
 
        For hypothesis two, Pearson product-moment correlation coefficients were computed to 
examine multicollinearity and to assess the association between continuous variables and each 
memory outcome; independent t-test and ANOVA analyses were used to examine differences in 
memory performance for categorical variables. A series of multiple linear regression analyses 
using simultaneous methods were performed in the HF group. Three explanatory variables were 
entered in the regression model based on sample size. Each dependent memory task (OBK, ISLT, 
ISLT-DR) was entered in separate regression equations.  Independent variables were age, heart 
disease severity (DASI and NYHA Class entered in separate equations), and postmenopausal 
symptoms associated with estrogen decline. The covariate was years of education, which 
influences cognitive function. Finally, additional regression models were examined to evaluate 
variables that were significant in univariate analyses (comorbidity and HF type). First, age was 
entered because it is known to affect memory performance.
13, 34, 35
   Next, comorbidity and HF 
type were entered. 
        For hypothesis one, power analyses indicated that a sample size of 64 participants in each 
group was required to detect the mean difference between the two groups with a power of 0.8. 




sample size needed was 76 in the HF group to obtain a power of 0.80 with a medium effect size 
and alpha at 0.05, as determined by inclusion of 3 explanatory variables in the regression model.
 
73
 Regression diagnostics were carried out to test the assumptions underlying regression analysis 
(independence, normal distribution, linearity, homoscedasticity).
 74
All analyses were conducted 
using SPSS version 17. 
Results 
Characteristics of sample 
        During the recruitment, 108 women with HF met the inclusion criteria and 76 of them (70%) 
were enrolled in the study. Reasons for not participating were: lack of availability, not interested, 
too sick, aversion to memory testing, disapproval of family member. No significant differences 
were found between women with HF who did and did not participate the study in terms of age, 
postmenopausal period, NYHA functional class, and HF duration. A total of 140 participants 
were included in the current study, including 76 women with HF and 64 healthy women. The 
characteristics of the participants are presented in Table 2.1. The demographic characteristics of 
the two groups were comparable: the sample was primarily Taiwanese; there were no group 
differences in age, marital status, years of education, and whether participant lived alone or not.    
More healthy participants were employed.          
        Compared with healthy women, women with HF had significantly higher systolic blood 
pressure, more comorbid diseases, worse perceived functional capacity and poorer mental status.  
The women with HF also had more postmenopausal symptoms associated with estrogen decline. 
No differences were found between the groups in terms of other variables related to menopause, 
including age at menopause, duration of menopause, ever taking hormone replacement therapy 




Memory performance in HF 
        The neuropsychological test scores of women with and without HF are presented in Table 
2.2. Reaction times for DET were significantly longer among women with HF, indicating a 
slower psychomotor response in this group. There were no differences between women with HF 
and healthy women on tests of IDN.  The scores in women with HF were significantly lower than 
healthy women on two of four memory outcomes. Women with HF had significantly worse 
scores on tests of working memory (OBK) and verbal memory (ISLT and ISLT-DR). The scores 
of visual memory (OCL and CPAL) in women with HF were lower compared with healthy 
women, but the difference did not reach significance. Of the memory domains tested, ISLT and 
ISLT-DR had lower mean z scores (z score= -.74 and -.77) compared to DET, IDN, OBK, OCL, 
and CPAL tasks (z score= -.61, -.15, -.44, -.40, and -.38), indicating that the verbal memory was 
the most affected (Figure 2.1). Hypothesis one was supported in the study.  
Factors associated with memory performance in HF         
          In univariate analyses, age was significantly correlated with OBK (r= -.56, p <.001), ISLT 
and ISLT-DR (r = -.62, p <.001; r = -.64, p <.001). Women in more severe NYHA Classes 
performed significantly worse in verbal memory recall tasks (F = -3.28, p = .026). However, HF 
severity (DASI) and postmenopausal symptoms associated with estrogen decline were not 
associated with any memory tasks. In addition, associations between demographic and clinical 
variables and memory outcomes were small to moderate. Duration of menopause was 
significantly correlated with OBK (r = -.50, p <.001), ISLT and ISLT-DR (r = -.52, p <.001; r = 
-.52, p <.001). Comorbidity was significantly correlated with OBK (r = -.23, p <.05), ISLT and 
ISLT-DR (r = -.37, p <.01; r = -.32, p <.01). Moreover, women with systolic HF had 




tasks (t = -2.67, p <.01; t = -3.12, p <.01) compared to women with diastolic HF. Finally, age and 
duration of menopause were highly correlated (r =.85, p <.05), so duration of menopause was not 
entered into multiple regression equations. Comorbidity and HF type were further evaluated in 
additional multiple regression models.  
        Hypothesis two was only partially supported in the study. The results of simultaneous 
multiple regression analyses for tasks in working memory (OBK) in the HF group are presented 
in Table 2.3. Age was the only significant explanatory variable in all of the models. Thus, older 
age was associated with worse working memory scores (OBK, , p < 0.001). Heart failure severity 
(DASI and NYHA Class), postmenopausal symptoms associated with estrogen decline, 
comorbidity, and HF type did not significantly contribute to performance of working memory. 
        For verbal memory tasks (Table 2.4 and Table 2.5), age and comorbidity significantly 
influenced ISLT (total recall) scores. Thus, being older and having more comorbidities were 
associated with worse ISLT (total recall) scores. Age and comorbidity accounted for 46% of 
variance in ISLT (Total Recall, R
2
 = .46).  Age, NYHA Class IV, comorbidity, and HF type were 
significantly related to poor verbal memory performance on ISLT-DR. In separate models, age 
and NYHA Class IV explained ISLT-DR (R
2
 = .46); age, comorbidity, and HF type accounted 
for 48% of variance in ISLT-DR (R
2
 = .48). Another heart failure severity measure (DASI) and 
postmenopausal symptoms associated with estrogen decline were not significant explanatory 
variables in any of the models of verbal memory. 
        Finally, all regression models were rerun with years of education entered as a covariate. In 
models for working memory, years of education was a significant covariate (OBK; t =2.18, p = 
033; t = 2.01, p = 0.049). In models for verbal memory, years of education was a significant 





        This is one of the first studies to examine memory performance and its associated factors in 
Taiwanese postmenopausal women with HF.  The results provide important insights into 
memory performance in Taiwanese postmenopausal women with HF. First, this sample of 76 
women with HF had poorer performance in working memory and verbal memory compared with 
64 healthy women.  Second, age was significantly associated with working memory; age, HF 
severity, comorbidity, and HF type were significant explanatory variables for verbal memory.   
        In the current study, women with HF had poorer performance on tests of working memory 
and verbal memory compared with healthy women. These results are consistent with and extend 
the work of past HF studies that combined men and women participants. 
9, 11, 13, 30, 34, 38 
As few 
studies have reported gender difference in cognitive deficits in HF, our study extends previous 
work by focusing on women, using valid objective neuropsychological tests to measure memory 
performance, and including a comparison group matched on age and education.  Furthermore, 
the current results were obtained from a culturally different sample than other studies, and 
consequently validate findings observed in patients from the United States and Europe. Poor 
memory performance may be related to difficulties in daily living activities and adhering to long-
term self-care behaviors. 
11, 12 
Therefore, it is important for nurses to identify memory deficits 
and assist healthcare providers in referring patients for advanced assessment. 
        Although memory deficits associated with systolic HF have been extensively studied, less is 
understood about the memory performance for patients with diastolic HF. In this study, most of 
the women with HF had diastolic HF (n=65, 85%). Memory deficits in these women were 
similar to memory deficits in patients with systolic HF in past studies. 
9, 38, 57, 75   
In diastolic heart 




stroke volume and cardiac output are reduced .
76  
This finding is important because it supports 
the theory that decreased cardiac output leading to inadequate cerebral perfusion and 
oxygenation is associated with memory deficits in diastolic HF. Working memory and episodic 
memory deficits are consistent with multiple brain structure damage in patients with HF, 
including loss of gray matter in the frontal cortex and parahippocampal areas, 
77
 reduced gray 
matter in the areas of hippocampus and hippocampus output fibers,
32 
and reduced mammillary 
body volume and cross-sectional areas of the fornix fibers. 
33 
 
        As hypothesized, age was significantly negatively related to all memory measures, 
including working, verbal, and visual memory. This is consistent with past HF studies relating 
age to decline in different domains of memory. 
7, 9, 13   
The age-related memory decline was 
associated with anatomical, electrophysiological, and synaptic plasticity changes in the 
hippocampus. 
78, 79   
This finding is particularly important to clinical practice because most 
patients with HF are elderly.
 
 Interventions to improve memory deficits in older patients with HF, 
such as cognitive training or exercise, have not been tested.  
         HF severity was significantly associated with verbal memory performance, consistent with 
previous studies.
 13, 37, 80 
 
 
In the current study, most women had diastolic HF. More severe 
NYHA Class was associated with poor verbal memory as measured by ISDL-DR. We are 
uncertain as to why there was no association between NYHA class and working or visual 
memory, in contrast to previous studies.
 13, 37   
It is possible that results were due to the 
heterogeneous measures that were used for assessing working memory and visual memory.  
Another explanation may be that most of the participants (75%) were NYHA functional class II. 
Further analyses should use another indicator for HF severity (ejection fraction, EF) to explore 




        No association was found between estrogen decline and memory performance in the current 
study. One possible explanation is that measurement issues limited the ability to detect 
relationships by using self-reported postmenopausal symptoms related to estrogen decline 
without measuring serum estrogen level. Moreover, it is possible that estrogen levels had 
remained low for a time period after menopause, 
81 
which may have limited impact on memory 
function in postmenopausal women with HF. Further studies are needed that include serum 
estrogen concentrations and recruitment of women with HF in different menopausal stages in 
order to understand the impact of estrogen decline on memory function. 
        This study provides evidence that comorbidities have a small detrimental influence on 
measures of verbal and visual memory. This effect is present and beyond the influences of age, 
education, and HF type. These findings contrast with a previous study that included 249 HF 
patients, where multiple comorbidities as measured by the Charlson Comorbidity Index were not 
associated with cognitive deficits.
 38 
The score was weighted by disease severity using one, two, 
three or six points; total comorbidity scores were not related to cognitive deficits. However, our 
study examined comorbidity using number of medical diseases rather than using severity level. A 
previous study found that patients with HF had a high rate of chronic diseases (an average of 5 
chronic diseases), with hypertension, cardiac arrhythmias, hyperlipidaemia, and diabetes mellitus 
most frequently reported.
 82 
These heart and circulation comorbidities were known to be related 
to cognitive function. 
9, 37
 It is not surprising that our HF sample, which had more comorbidities, 
would present with poorer memory performance.  
        The association between HF type and verbal memory (ISLT-DR) was unexpected. The 
findings indicate that women with systolic HF had poorer verbal memory compared with women 




and memory function. The sample size of women with systolic HF in our study was small (n=11). 
Considering that this association was not included in our original hypothesis, further work is 
needed to examine the possible impact of HF type on memory performance. 
Limitations 
        This study has a number of limitations.  First, estrogen decline was measured by self-
reported menopausal symptoms that may not actually reflect estrogen condition. Further studies 
should collect blood estrogen samples that can directly confirm the relationship between estrogen 
level and memory outcomes. In addition, results could not be generalized to all women with HF 
because we included only postmenopausal women without other conditions that may cause 
cognitive deficits or psychiatric problems. 
Conclusion 
        In conclusion, results indicated that working memory and verbal memory are poorer in 
women with HF compared to healthy participants. Several factors, such as age, HF severity, 
comorbidity, and HF type, which affect memory performances, were identified. Further studies 
are needed to determine mechanisms of memory deficits in women with HF and how these 
influence women’s lives and self care, and to develop interventions such as cognitive training. 
This study has important clinical implications. Women with HF who have significant memory 
decline may be compromised in their ability to learn to adhere to such things as complex 
medication schedules and dietary therapies in ways that interfere with the goal of successful 
living with this illness. Nurses and health care providers should assess women with HF at risk of 
poor memory (ex., older patients, patients with severe HF, and patients with more chronic 
diseases), educate health and self-care behaviors to reduce risk of memory decline, and develop 









(n = 76) 
 Healthy  







Age, mean (SD) 69.4 (8.9) 69.7 (10.2) 68.9 (7.1) t=0.53 0.59 
 Race, n (%)    Fisher’s 
exact test 
0.02* 
    Taiwanese 104 (74.3) 49 (64.5) 55 (85.9)   
    Mainland China     26 (18.6) 19 (25) 7 (10.9)   
    Hakka 8 (5.7) 6 (7.9) 2 (3.1)   
    Aborigine      2 (1.4) 2 (2.6) 0 (0)   
Marital status, n (%)                                Fisher’s 
exact test 
0.16 
    Married 102 (72.9) 61 (80.3) 41 (64.1)   
    Single  3 (2.1) 1 (1.3) 2 (3.0)   
    Divorced 6 (4.3) 2 (2.6) 4 (6.3)   
    Widowed 29 (20.7) 12 (15.8) 17 (26.6)   
Education, mean (SD)                              7.6 (3.2) 7.3 (3.3) 8.0 (3.1)    t=-1.31 0.19 
Employment, n (%)                                             χ
2
=11.25 0 .001** 
    No 115 (82.1) 70 (92.1) 45 (70.3)   
    Yes 25 (17.9) 6 (7.9) 19 (29.7)   
Live alone, n (%)                                χ
2
=1.28 0.52 
    No 115 (82.1) 64 (84.2) 51 (79.7)   
    Yes 25 (17.9) 12 (15.8) 13 (20.3)   
Systolic blood pressure, 
mean (SD) 
129.5 (15.8) 135.5 (17.5) 122.3 (9.5) t=5.34 < .001*** 
Diastolic blood pressure, 
mean (SD) 
75.3 (8.9) 76.1 (10.2) 74.4 (6.9) t=1.1 0.27 
Comorbidity number, 
mean (SD) 
1.1 (1.0) 1.8 (0.9) 0.2 (0.4) t=12.16 < .001*** 
Age at menopause,  
mean (SD) 
50.0 (5.1) 50.4 (5.8) 49.6 (4.1) t=0.83 0.407 
Months since 
menopause, 
 Mean (SD) 
232 (116) 232 (133) 231 (94) t=0.08 0.929 
Ever take HRT, n (%)    χ
2
=0.00 0.983 
     No 95 (67.9) 51 (67.1) 44 (68.8)   
     Yes 43 (30.7) 23 (30.3) 20 (31.2)   









     No 136 (97.1) 72 (94.7) 64 (100)   
     Yes 4 (2.9) 4 (5.3) 0 (0)   
MoCA, mean (SD) 26.2 (3.3) 25.1 (3.7) 27.5 (2.1) t=-4.54 < .001*** 
Duke Activity Status 
Index, mean (SD) 
30.8 (15.1) 21.6 (11.3) 41.7 (11.5) t=-10.29 < .001*** 
The Greene Climacteric 
Scale , mean (SD) 
14.6 (9.5) 17.9 (10.4) 10.8 (6.8) t=4.69 < .001*** 
Left Ventricular 
Ejection Fraction, mean 
(SD)    
 60.9 (3.8)    
NYHA class, n (%)      
    Class I  6 (7.9)    
    Class II  57 (75)    
    Class III  11 (14.5)    
    Class IV  2 (2.6)    
Month of HF, mean(SD)  35.7 (28.4)    
Type of HF, n (%)      
    Systolic HF  11 (14.5)    
    Diastolic HF  65 (85.5)    
      
Note.   HRT= Estrogen replacement therapy; MoCA= Montreal Cognitive Assessment; 
NYHA=New York Heart Association; HF=heart failure; Values are expressed as numbers (%). 
Percentage is expressed as valid percentage, which excludes missing data  
 





Table 2.2. Means and Standard Deviations for CogState tests  
 
 HF (n=76)    
(Mean ± SD) 
Healthy (n=64)  









      
   DET, speed
a
                   2.7 ± 0.1   2.6 ± 0.1   7.6 0.007 -0.61** 
   IDN, speed
a
   2.7 ± 0.09   2.7 ± 0.0   0.2 0.65 -0.15 
   OBK, accuracy
b
   1.0 ± 0.2   1.1 ± 0.1   4.3 0.04 -0.44* 
   ISDL, total
b
 20.2 ± 5.7 23.4 ± 4.4 14.7 < .001 -0.74*** 
   ISDL, delayed recall
b
   6.8 ± 2.8   8.3 ± 1.9 13.9 < .001 -0.77*** 
  OCL, accuracy
b
   0.9 ± 0.1   0.9 ±0.09   3.6 0.06 -0.40 
  CPAL, error
a
 96.7 ± 61.3 79.3 ± 40.3   2.8 0.10 -0.38 
 
Note. .   *P < .05   **P <.01     ***P< .001,  HF=heart failure; DET= Detection task; IDN= 
Identification task; OBK= One Back Task; ISLT= the International Shopping List Task, total; 
ISLT-DR= the International Shopping List Task, delayed recall; OCL= One Card Learning Task; 
CPAL= Continuous Paired Associate Learning 
a
Lower score=better performance.  
b
Higher score=better performance.  
c
P value for analysis of covariance adjusting for age and education. 
d





Table 2.3. Multiple Regression Analysis: Explanatory Variables for Working Memory (One 
Back Task, Accuracy) in Women with HF 
Models Variables B SE B Beta  t P value 
       
1
 a
  Age -0.02 0.003 -0.65 -5.96 <0.001 
 GCS -0.001 0.002 -0.06 -0.56 0.58 
 DASI -0.01 0.002 -0.21 -1.92 0.06 
       
2
 b
  Age -0.01 0.002 -0.57 -5.59 <0.001 
 GCS  0.00 0.002 -0.01 -0.08 0.94 
 NYHA IV  0.08 0.16  0.05  0.54 0.59 
       
3
 c
 Age -0.01 0.002 -0.50 -5.08 <0.001 
 Comorbidity -0.04 0.03 -0.14 -1.41 0.16 
 HF type  0.10 0.07  0.15  1.5 0.14 
Note: HF=Heart Failure; GCS= the Greene Climacteric Scale; DASI= Duke Activity Status 




= .35, Adjusted R
 2




= .31, Adjusted R
 2




= .35, Adjusted R
 2






           Table 2.4. Multiple Regression Analysis: Explanatory Variables for Verbal Memory 
(International Shopping List Task, Total Recall) in Women with HF 
Models Variables B SE B Beta  t P value 
       
1
 a
 Age -0.35 0.06 -0.63 -5.94 <0.001 
 GCS  0.02 0.05  0.04 0.44 0.66 
 DASI -0.02 0.05 -0.05 -0.43 0.67 
       
2
 b
 Age -0.33 0.05 -0.59 -6.22 <0.001 
 GCS  0.03 0.05  0.05  0.52 0.60 
 NYHA IV -3.81 3.33 -0.11 -1.15 0.26 
       
3
c
 Age -0.30 0.05 -0.54 -6.06 <0.001 
 Comorbidity -1.59 0.53 -0.26 -3.00 0.004 
 HF type  2.78 1.42  0.17  1.96 0.05 
Note: HF=Heart Failure; GCS= the Greene Climacteric Scale; DASI= Duke Activity Status 




= .38, Adjusted R
 2











= .48, Adjusted R
 2





             Table 2.5. Multiple Regression Analysis: Explanatory Variables for Verbal Memory 
(International Shopping List Task, Delayed Recall) in Women with HF  
Models Variables B SE B Beta  t P value 
       
1
a
 Age -0.20 0.03 -0.72 -7.06 <.001 
 GCS -0.03 0.03 -0.12 -1.31 0.20 
 DASI -0.03 0.03 -0.12 -1.18 0.24 
       
2
b
 Age -0.18 0.03 -0.63 -7.10 <.001 
 GCS -0.03 0.02 -0.10 -1.20 0.24 
 NYHA IV -4.27 1.54 -0.24 -2.77 0.007 
       
3
c
 Age -0.16 0.02 -0.56 -6.49 <.001 
 Comorbidity -0.63 0.26 -0.21 -2.42 0.02 
 HF type  1.72 0.69  0.21  2.49 0.02 
Note: HF=Heart Failure; GCS= the Greene Climacteric Scale; DASI= Duke Activity Status 




= .43, Adjusted R
 2




= .48, Adjusted R
 2




= .50, Adjusted R
 2






























Note. *P < .05   **P <.01     ***P< .001; HF=heart failure; DET= Detection task; IDN= 
Identification task; OBK= One Back Task; ISLT= the International Shopping List Task, total; 
ISLT-DR= the International Shopping List Task, delayed recall; OCL= One Card Learning Task; 
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Validation of the Chinese Version of the CogState Computerized Cognitive Assessment 
Battery in Taiwanese Patients with Heart Failure 
Abstract 
Aims and objectives: To evaluate the validity of the Chinese version of the CogState battery, a 
computerized neuropsychological test battery among women with heart failure (HF) in Taiwan. 
Background: The CogState computerized battery has been validated in many countries, but not 
in Taiwan. 
Design: A cross-sectional descriptive study.  
Methods:  A convenience sample consisted of 76 women with HF and 64 healthy women from 
one medical center in Northern Taiwan. Participants completed the Chinese version of the 
CogState battery and the Montreal Cognitive Assessment (MoCA).  Construct validity of the 
Chinese version of the battery was evaluated by exploratory factor analysis and known-group 
comparisons. Convergent validity of the CogState tasks was examined by Pearson correlation 
coefficients. 
Results: Principal components factor analysis with promax rotation showed two factors 
reflecting the speed and memory dimensions of the tests. Scores for CogState battery tasks 
showed significant differences between the HF and healthy control groups. The convergent 




Conclusion: The Chinese CogState Computerized Cognitive Assessment Battery has 
satisfactory validity. It has potential use with HF patients for both research and practice.  
Key words: Heart failure, CogState Computerized Cognitive Assessment Battery, factor analysis 








        Heart failure is a major and growing problem worldwide and is associated with significant 
mortality and frequent hospitalizations (Gwadry-Sridhar, Flintoft, Lee, Lee, Guyatt, 2004). 
Cognitive deficits are common in patients with HF; prevalence ranges from 25% to 50% among 
this population (Bennett & Sauvé, 2003; Pressler, 2008; Vogels, Oosterman, et al., 2007). 
Compared to healthy persons, patients with HF have shown cognitive deficits in areas including 
attention and concentration, memory, psychomotor speed, and executive function (Bennett, 
Sauvé, & Shaw, 2003). One of the most likely etiologies of cognitive decline in HF is inadequate 
cerebral perfusion and cerebral hypoxia caused by low cardiac output (Bennett &, Sauvé, 2005; 
Pullicino, & Hart, 2001; Taylor & Stott, 2002). Studies report that HF patients are at four times 
increased risk for cognitive deficits compared with matched controls (Sauvé, Lewis, 
Blankenbiller, Rickabaugh, & Pressler, 2009). Qiu et al. (2006) have demonstrated that people 
with HF have twice the risk of dementia and Alzheimer disease over 9 years. 
        Complaints of memory impairment are among the most frequently reported cognitive 
deficits in HF patients, affecting approximately 40% of them (Hawkins et al., 2012; Pressler, 
Subramanian, et al., 2010; Putzke et al., 1997; Sauvé et al., 2009). Recently, researchers found 
that 48% of HF patients had impaired memory, but with preserved performance in other 
cognitive domains (Miller et al., 2012). Evidence supports that HF is associated with changes in 
brain structures which are critical for memory functioning. For example, HF patients had gray 
matter loss in brain areas involving cognition, including the prefrontal cortex areas critical to 
working memory (Woo, Macey, Fonarow, Hamilton, & Harper, 2003). Brain injuries emerged in 
several areas in HF patients, including the hippocampus, fornix, thalamus, mammillary body and 




important roles in episodic memory (Budson, 2009). Moreover, studies demonstrated that HF 
patients showed significant medial temporal lobe atrophy that was significantly negatively 
correlated with memory performance (Vogels, Flier, et al., 2007; Vogels, Oosterman, et al., 
2007). 
        Empirical studies have consistently demonstrated the significant impacts of memory on 
daily activities, HF self-care, and mortality. For example, researchers reported verbal memory 
has been found to successfully explain performing instrumental activities of daily living 
(Hammers, Jung, et al., 2012). In addition, patients with poor HF self-care had impaired memory 
(Riegel, Dickson, Goldberg, & Deatrick, 2007). The deficits in memory may result in 
forgetfulness and poor learning ability that lead to failure to adhere to treatment regimens 
(Dickson, Tkacs, & Riegel, 2007). In a study among 166 HF patients, memory loss as measured 
by verbal list-learning was the most significant cognitive deficits to predict 12-month mortality 
(Pressler, Kim, et al., 2010). Although memory deficits have consistently been reported by 
patients who suffer from HF, there are no generally accepted measures for memory screening in 
them.  
        The CogState battery is a standardized, computerized neuropsychological test battery that 
was developed to measure cognitive function in large samples (Fredrickson et al., 2010). It is 
comprised of subsets that tasks assess psychomotor speed, attention, working memory, visual 
and verbal memory, executive function, and social cognition (Maruff et al., 2009). The battery 
has demonstrated sound psychometric properties. Test-retest reliability has been shown to be 
satisfactory, with 6-day test-retest correlations in patients with coronary surgery ranging from 
0.61 to 0.92. In a recent HF study, eight-week test-retest correlations ranged from 0.53 to 0.78 




CogState tests and traditional neuropsychological measures; most of the correlations are 
moderate to large (De Jager et al., 2009; Pietrzak et al., 2009; Yoshida et al., 2011). The 
CogState test battery significantly differentiated cognitive performance between persons with 
schizophrenia (n=121) and matched participants in the control groups (n=120) (Pietrzak et al., 
2009). Stability was acceptable, with intra-class correlation coefficients ranging from 0.65 to 
0.91 in older adults over 12 months (Fredrickson et al., 2010). The battery identified mild 
cognitive impairment with good sensitivity (78%) and specificity (90%) among older adults (De 
Jager et al., 2009). The International Shopping List (ISL) subtest of the computerized CogState 
battery has performed comparably with the Hopkins Verbal Learning Test-Revised and 
significantly predicted daily functioning, indicating it could be a sensitive tool for evaluating 
cognitive change in HF (Hammers, Jung, et al., 2012). 
        Most evidence has shown that subsets of the CogState tasks are sensitive to cognitive 
changes in groups such as those with schizophrenia (Maruff et al., 2009; Pietrzak et al., 2009), 
mild traumatic brain injury (Maruff et al., 2009), dementia or Alzheimer’s disease (Hammers, 
Spurgeon, et al., 2012; Lim, Ellis, et al., 2012; Maruff et al., 2009), and mild cognitive 
impairment (Darby, Maruff, Collie, & McStephen, 2002; De Jager et al., 2009). However, only 
one study with a small sample size evaluated the utility of the CogState verbal memory subset in 
an HF population (Hammers, Jung, et al., 2012).   
        Given the high prevalence and importance of memory deficits in HF, the routine use of 
validated and brief, but sensitive, assessment instruments is needed for early detection of 
memory impairment in this population. Moreover, despite that the CogState computerized 
battery has been evaluated in languages other than English, including French, Korean (Lim, 




a Chinese population has not yet been examined. Therefore, the purpose of the current study was 
to evaluate the validity and reliability of the Chinese version of the CogState tests in Taiwanese 
patients with HF.  The hypotheses were that the Chinese version would demonstrate validity as 
evaluated by: (1) exploratory factor analysis to investigate the internal structure of CogState tests; 
(2) differences between patients with HF and healthy control groups; and (3) correlations with a 
standard measure of global cognitive function.  
Methods 
Participants 
        A cross-sectional design was used. The study was conducted in a hospital in Taipei, Taiwan 
during November 2010 through October 2011. A convenience sample of 76 women with chronic 
HF was recruited from cardiovascular clinics and 64 age- and education- matched healthy 
women were recruited from outpatients of the gynecology clinic, the women’s health center, and 
volunteers in the same hospital. Women with HF were eligible for participation in the study if 
they were age 50 years and older, their last menstrual cycle was completed more than 12 months 
previously, had a diagnosis of HF of at least 6 months, and could read and speak Mandarin. 
Women were eligible for participation in the age- and education- matched healthy group if they 
fulfilled the same criteria and had, no major medical conditions. Exclusion criteria for the two 
groups included having conditions known to cause cognitive deficits or the presence of impaired 
sensory problems. Women who had hypertension with blood pressure less than 140/90 mmHg or 
hyperlipidemia with cholesterol less than 200 mg/dl were eligible for the healthy group.  
Procedures 
        After obtaining approval from the Institutional Review Board of the University of Michigan 




the hospital who met inclusion criteria and explained the purpose and procedures of the study. 
Written consents were obtained from all participants; data were collected by face-to-face 
interviews. The entire time for data collection was approximately 60 to 90 minutes. 
Demographic and clinical information was collected using questionnaires and from medical 
records. The MoCA and the computerized CogState tests were administered by an experienced 
nurse who was trained by a neuropsychologist.  
        The tasks in the Chinese CogState battery were translated from English version and 
provided by CogState Company using a linguistically validated process to produce an instrument 
that is conceptually equivalent to the English version. The validation process included seven 
steps: conceptual definition, forward translation, backward translation, pilot testing, international 
harmonization, proofreading, and report (MAPI Institute, 2011).
 
Measures 
        The MoCA was used to measure global cognitive function. It was developed as a screening 
tool for mild cognitive impairment (MCI) and early dementia (Nasreddine et al., 2005). The 
MoCA is a 10-minute test and includes items on visuospatial abilities, naming, short-term 
memory recall, attention, language, verbal abstraction, memory, and orientation. The MoCA was 
selected as a measure of global cognitive function because it has been demonstrated to be more 
sensitive in detecting cognitive impairment in HF patients than another commonly-used 
instrument, the Mini-Mental Status Examination (MMSE) (Athilingam et al., 2011). Possible 
MoCA scores range from 0 to 30; higher scores indicate better global cognitive function. Using a 
cutoff score of 26 to identify MCI, a sensitivity of 90% and a specificity of 87% were found 
among 93 patients with mild Alzheimer’s disease (AD) and 90 healthy elderly controls in the 




conducted in Japan and Taiwan. Using a cut-off point of 25/26, a study in Japan reported a 
sensitivity of 93% and a specificity of 87% in detecting MCI in 96 older adults (Fujiwara et al., 
2010). A Taiwan study reported a sensitivity of 92% and specificity of 78% for MCI by using an 
optimal cut-off score of 23/24 among 98 patients with AD, 71 with MCI, and 38 normal controls 
(Tsai et al., 2012). The criterion validity, internal consistency and test-retest reliability were 
satisfactory in the Chinese version of MoCA (Wong et al., 2009). 
        The Chinese version of the CogState computerized memory subtests was used by the 
authors to measure memory function in a study of Taiwanese women with HF (Table 3-1), 
described elsewhere (De Jager et al., 2009; Fredrickson et al., 2010; Lim et al., 2009).  This test 
battery was selected because of its brevity, good usability, culture-free stimuli (i.e., playing cards) 
and because it was valid, reliable, and sensitive in detecting decline over time in older adults 
(Table 3-2) (Cysique, Maruff, Darby, & Brew, 2006; Pietrzak et al., 2009; Darby et al., 2002).  
Six tasks were selected from the battery, including four measuring working and episodic memory.   
        Two CogState tasks measuring psychomotor speed and attention were evaluated.  The 
Detection task (DET) is a psychomotor speed task that requires participants to respond as soon as 
possible when a playing card in the center of the computer screen flips over. The Identification 
task (IDN) is a measure of visual attention that assesses speed of performance. Participants are 
asked to press the ‘yes’ button if the card appearing in the center of the computer screen is red 
and the ‘no’ button if the card is black as soon as possible (Collie et al., 2007). The task ends 
when 30 correct trials have been completed. 
 
A lower score indicated better performance.  
         Working memory was measured by OBK. The One Back Task (OBK) is a measure of 
working memory that assesses accuracy of performance. The participant presses
 
the ‘yes’ button 




different (Cysique et al., 2006). Thirty correct trials were required for completion. A higher score 
indicates better performance
 
        Verbal memory was measured by International Shopping List Task (ISLT), which included 
a 3-trials immediate free recall of a series of 12-word lists, followed by 20-minute delayed recall 
for the word list. The individuals are required to remember a list of shopping items that are 
relevant to their culture. Studies have reported that performance is equivalent among English, 
French, Malay, and Mandarin Chinese versions of the ISLT (Lim et al., 2009). The ISLT has 
been shown to correlate with the Hopkins Verbal Learning Test-Revised (HVLT–R) (r = .47 
to.75) and has adequate stability in 40 patients with chronic HF (r = .53 to.68) (Hammers, Jung, 
et al., 2012). The test-retest correlations in 50 patients with mild AD were 0.85 for ISLT and 
0.45 for ISLT delayed recall trail (ISLT-DR) (Thompson et al., 2011). Possible scores range 
from 0 to 36 in the ISLT first 3 trails and 0-12 in the ISLT-DR. A higher score indicates a better 
verbal memory performance.  
        Visual memory was measured by the One Card Learning Task (OCL) and the Continuous 
Paired Associate Learning Task (CPAL).  The OCL assesses accuracy of performance. Similar in 
presentation to the ONB task, the participants press the “yes” button if the card has appeared 
before or the “no” button if it has not appeared. The OCL ends after 42 trials are completed 
(Fredrickson et al., 2010). A higher score indicates a better performance. The CPAL requires 
participants to learn sets of pattern–location associations in acquisition and learning phases. In 
the first phase, the participant is asked to remember the identical shape patterns hidden beneath 
the peripheral locations. In the learning phase, each pattern is presented in the centre of the 




location (O'Donnell, Pietrzak, Ellis, Snyder, Maruff, 2011). 
 
It is scored as the total number of 
errors across seven rounds, with lower scores indicating better visual memory performance. 
Statistical Analysis 
        SPSS 17.0 software was used for statistical analysis. Descriptive statistics (proportions, 
means, medians, and standard deviations) were used to summarize demographic and clinical 
variables, scores for CogState computerized tasks and MoCA results. Student’s t-tests, chi-
square tests, and Fisher’s exact tests were used to examine differences between groups. 
        For hypothesis one, the factor structure of the CogState tasks was determined by performing 
exploratory factor analysis using principal components analysis with varimax rotation. The 
Kaiser–Meyer–Olkin (KMO) test and Bartlett’s test of sphericity were used to examine sampling 
adequacy and model appropriateness for performing factor analyses. The following criteria were 
used for factor extraction: having eigenvalues greater than 1, factor loadings higher than 0.30, 
and interpretability (Field, 2005).  For hypothesis two, analysis of covariance (ANCOVA) were 
used for each test of CogState battery (DET, IDN, ONB, ISLT, ISLT-DR, OCL, and CPAL) to 
compare differences in means adjusting for age and education between the HF and healthy 
groups. For hypothesis three, the correlation was examined by calculating Pearson correlation 
coefficients for CogState tasks (DET, IDN, ONB, ISLT, ISLT-DR, OCL, and CPAL) and the 
MoCA.   
Results 
Sample Characteristics  
        Table 3.3 shows characteristics of the study participants. The sample was composed of 76 
women with HF and 64 healthy women. Mean age of participants was 69.4 years (SD=8.9). The 




and were not employed (82.1%). Women with HF had significantly higher systolic blood 
pressures and more comorbid diseases compared to healthy women. Moreover, most women 
with HF had diastolic HF (85.5%) and were in New York Heart Association (NYHA) class II 
(75%).   
Performance in CogState tasks and MoCA 
        The score mean and standard deviation of the tasks in CogState battery among groups were 
presented in Table 3.4 and Figure 3.1. Compared with healthy participants, women with HF had 
lower scores in the tests of OBK (mean=1.0; SD=0.2), ISLT (mean=20.2; SD=5.7), and ISLT-
DR (mean=6.8, SD=2.8). The scores of the IDN and OCL tests were similar between two groups.  
Women with HF also had higher score in the tests of DET (mean= 2.7; SD=0.1), and CPAL 
(mean=96.7; SD=61.3).The mean MoCA scores were 25.1 (SD=3.7) in HF group and 27.5 
(SD=2.1) in healthy group (Table 3-3). 
Exploratory Factor analysis  
        An exploratory factor analysis using principal components analysis was performed to 
determine the number and the content of factors underlying the CogState tasks (Table 3.5). The 
Kaiser–Meyer–Olkin test measure for the data was 0.724, indicating sampling adequacy and 
compact patterns of correlation; the factor analysis produced distinct and reliable factors (Field, 
2005).  Bartlett’s test of sphericity reached statistical significance (p < .001), which supported 
that some relationships between the variables existed (Field, 2005). Oblique promax rotations 
were used because the CogState  factors were assumed to be correlated.  This showed the 
presence of two factors with eigenvalues > 1, explaining 64.6% of the total variance. The first 
factor accounted for 44.95% of the total variance and contained ISLT, ISLT-DR, CPAL, OBK, 




accounted for 19.69 % of the total variances and contained two tests (DET and IDN); it was 
labeled “speed” . Factor loadings ranged from 0.90-0.91. 
 Group comparison   
         The ANCOVA resulted in statistically significant differences (p < 0.05) for CogState 
scores between the HF and healthy groups (Table 3.4). Women with HF reported higher 
psychomotor speed score than did healthy women (DET, p < 0.01) and lower scores on working 
memory (OBK, p < 0.05) and verbal memory tasks (ISLT, p < 0.001; ISLT-DR, p < 0.001), after 
controlling for age and education years, providing evidence that further supported the construct 
validity of the CogState battery.  In addition, the HF group showed higher scores in CPAL 
performance than the healthy group, but the difference did not reach significance. No difference 
was found in the tests of the IDN and OCL between women with HF and healthy women. 
Correlation between CogState tasks and MoCA 
        The relationship between each individual test score of the CogState and MoCA are 
presented in Table 3.6.  Significant correlations were also shown between MoCA and the OBK 
(r = 0.42, p < 0.001), ISLT (r = 0.57, p < 0.001), ISLT-DR (r = 0.64, p < 0.001), OCL (r = 0.40, 
p < 0.001), CPAL (r = 0.40, p < 0.01), which demonstrate convergent validity of these CogState 
tests in this population. In addition, the DET and IDN score of the CogState battery and MoCA 
were not significantly correlated in both HF and healthy control group.  
Discussion and Conclusion 
        This is the first study to report use of the Chinese version of a computerized 
neuropsychological test battery in an HF population. Results supported the hypothesis that the 
Chinese CogState subtests demonstrated good convergent validity and construct validity among 




        Findings of the exploratory factor analysis pointed to the common features of the selected 
CogState battery tasks, namely speed and memory, which support construct validity of the 
selected CogState battery items in this population. The OBK, OCL, and CPAL present visual 
stimuli in the center of the computer, and participants must memorize presentations to perform 
adequately. The ISLT, on the other hand, provides verbal stimuli that participants need to recall 
immediately or later and performance is based on how many words can be recalled correctly. For 
the remaining measures, such as DET and IDN, although the visual stimuli are presented in the 
middle of the computer screen, the participants are required to respond as quickly as possible. 
Four tasks loaded on a factor that labeled as memory, which included working memory (i.e., 
OBK) and episodic memory tasks (i.e., OCL, ISLT, and CPAL). Our findings are similar to 
those of Yoshida et al. (2011), who conducted a factor analysis for the CogState Schizophrenia 
Battery in 40 Japanese patients with schizophrenia. In our study, however, OBK was included in 
the memory factor, while Yoshida et al. (2011) found the OBK was not associated with any 
factor solution. This may be due to the small sample size of that study (N=40). 
        This is the first study to compare CogState results from HF population to those from a 
healthy control group. Results showed that HF patients scored significantly lower than the 
healthy controls group, which is consistent with previous findings using other standard 
neuropsychological tests (Pressler, Subramanian, et al., 2010; Sauvé et al., 2009; Vogels, 
Oosterman, et al., 2007). Women who have HF are more likely to demonstrate poor performance 
on most of the CogState memory tasks when compared to a healthy female control group. 
Although CPAL task results were not significantly different in the two groups, the HF group had 
more CPAL errors compared to the control group. These results are congruent with findings that 




(Schmidet, Fazekas, Offenbacher, Dusleag, & Lechner, 1991; Woo et al., 2003) as well as in 
brain regions associated with episodic memory (Woo et al, 2009; Kumar et al., 2009). 
        The Chinese CogState subtests were significantly correlated with MoCA in HF and control 
groups. The MoCA is considered to evaluate different cognitive abilities, including memory 
(Nasreddine et al., 2005), thus these results provided evidence that supports validity in the 
Chinese CogState memory subtests. The  English version of the selected CogState tests 
(DET,IDN,OBK, ISLT) was significantly correlated with standard neuropsychological tests and 
only ISLT was significantly correlated with MMSE in a small HF sample (N=40) (Hammers, 
Jung, et al., 2012). Interesting, no association was found between the global cognitive measure 
(MMSE or MoCA) with DET or IDN in this current study or previous HF study (Hammers, Jung, 
et al., 2012). This may be because the DET and IDN are measures of psychomotor speed and the 
MMSE or MoCA did not measure any speed of response. The current study additionally found 
that memory subtests such as OBK, ISLT, OCL and CPAL had significant correlations with a 
global cognitive measure (MoCA). Compared to MMSE, the MoCA is a sensitive cognitive 
screening measure that can identify possible MCI in patients with HF (Cameron, Worrall-Carter, 
Page, Stewart, & Ski, 2012).  Future study is needed to compare correlations among the Chinese 
CogState subtests using standard neuropsychological tests in HF population. 
        There are some limitations of the study, including that a gold standard neuropsychological 
test was not to use to measure cognitive impairment. More research is needed to validate our 
results against such a gold standard neuropsychological testing. Although the study did not 
evaluate test-retest reliability of the Chinese CogState, other studies have reported acceptable 
test-retest reliability for its subtests in non-Chinese older adults and HF patients (Fredrickson et 




of the Chinese CogState.  Another limitation is that participants included only women with HF. 
It is not clear whether these results would be the same for men.  Although the battery was 
constructed for self-administration, some patients with HF had difficulties using a mouse to 
complete the CPAL task and required help from the investigator. For example, help to hold her 
hand with mouse together and move to the location she pointed. Use of a laptop with a touch 
screen is suggested to validate the CPAL task in future studies. 
        This study demonstrated that the CogState is a valid and reliable instrument to assess 
memory performance in women with HF in Taiwan, where we believe until now there has no 
research examining memory assessment and management. The current study showed that the 
CogState memory subtests were significantly correlated with MoCA tasks; were sensitive to 
memory impairment in Taiwanese patients with HF; loaded on a factor labeled as memory by a 
principal components analysis, and had acceptable internal consistency, suggesting that it could 
be a valid instrument for detecting memory impairment in this population. Future research is 
needed to address memory impairment in those with HF and to develop protocols for 
management of memory decline. 
Implications for clinical practice 
        As clinicians have a better understanding of memory deficit patterns in patients with HF, it 
is important that they provide improved care and treatment. Nurses play a critical role in 
assisting patients to plan long-term treatments toward the goal of successful living with HF. The 
CogState battery could be used to help detect memory deficits that may be subtle in the early 
stages of HF, and identify changes that provide insights into patients’ abilities to implement 
treatment accurately and consistently. Better interventions tailored to the needs of the HF 




Table 3.1. Tasks in the CogState Computerized Cognitive Assessment Battery  
Test Abbreviation Domain Outcome measure 
    
Detection task  DET Psychomotor speed Average log10 reaction 
times of correct 
responses 
Identification Task  IDN Attention Average log10 reaction 
times of correct 
responses 
One Back Task OBK Working memory Arcsine percentage of 
correct responses 
International Shopping List Task  ISLT Verbal memory Number of words 
recalled in 3 trials 
International Shopping List Task 
: Delayed recall  
ISLT-DR Verbal memory Number of words 
recalled after 20 
minutes   
One Card Learning Test OCL Visual memory Arcsine percentage of 
correct responses 
Continuous Paired Associate       
Learning Task  
CPAL Visual memory Number of errors made 





Table 3.2 Pearson’s Product-moment Correlations between CogState Tasks and 
Neuropsychological Tests in Previous Publications. 
Study DET IDN OBK ISLT ISLT-DR OCL CPAL 
Hammers et al., 
2012 (n=40) 
-0.35 -0.37 0.33-0.43 0.46-0.7 0.45-0.75   
Hammers et al., 
2012 ( n=22) 
0.50 0.45 0.47-0.52   NS   
Yoshida et al., 
2012 (n=80) 
0.34  NS 0.71   0.34 
Pietrzak et al., 
2009 (n=121) 
0.56-0.79 0.57 0.56-0.75 0.78  0.76  
Maruff et al., 
2009 ( n=253) 
0.52-0.81 0.49-0.78 0.54-0.81   0.57-
0.83 
 
Cysique et al., 
2006 (n=60) 
-0.29-0.60 -0.26-0.62      
Note. NS= not significant correlation; DET= Detection task; IDN= Identification task; OBK= 
One Back Task; ISLT= the International Shopping List Task, total; ISLT-DR= the International 
Shopping List Task, delayed recall; OCL= One Card Learning Task; CPAL= Continuous Paired 
Associate Learning. 









(n = 76) 
 Health  









Age, mean (SD) 69.4 (8.9) 69.7 (10.2) 68.9 (7.1) t=0.53 0.59 




    Taiwanese 104 (74.3) 49 (64.5) 55 (85.9)   
    Mainland China     26 (18.6) 19 (25) 7 (10.9)   
    Hakka 8 (5.7) 6 (7.9) 2 (3.1)   
    Aborigine      2 (1.4) 2 (2.6) 0 (0)   




    Married 102 (72.9) 61 (80.3) 41 (64.1)   
    Single  3 (2.1) 1 (1.3) 2 (3.0)   
    Divorced 6 (4.3) 2 (2.6) 4 (6.3)   
    Wiowed 29 (20.7) 12 (15.8) 17 (26.6)   
Education, mean (SD)                              7.6 (3.2) 7.3 (3.3) 8.0 (3.1)    t=-1.31 0.19 
Employment, n (%)                                              χ
2
=11.25 0.001** 
    No 115 (82.1) 70 (92.1) 45 (70.3)   
    Yes 25 (17.9) 6 (7.9) 19 (29.7)   
Live alone, n (%)                                χ
2
=1.28 0.52 
    No 115 (82.1) 64 (84.2) 51 (79.7)   
    Yes 25 (17.9) 12 (15.8) 13 (20.3)   
Systolic blood pressure, 
mean (SD) 
129.5 (15.8) 135.5 (17.5) 122.3 (9.5) t=5.34 < .001*** 
Diastolic blood pressure, 
mean (SD) 
75.3 (8.9) 76.1 (10.2) 74.4 (6.9) t=1.1 0.27 
Comorbidity number, 
mean (SD) 
1.1 (1.0) 1.8 (0.9) 0.2 (0.4) t=12.16 < .001*** 
Age at menopause,  
mean (SD) 
50.0 (5.1) 50.4 (5.8) 49.6 (4.1) t=0.83 0.407 
Months since 
menopause, 
 Mean (SD) 
232 (116) 232 (133) 231 (94) t=0.08 0.929 
Ever take HRT, n (%)    χ
2
=0.00 0.983 
     No 95 (67.9) 51 (67.1) 44 (68.8)   
     Yes 43 (30.7) 23 (30.3) 20 (31.2)   










     Yes 4 (2.9) 4 (5.3) 0 (0)   
MoCA, mean (SD)  26.2 (3.3) 25.1 (3.7) 27.5 (2.1) t=-4.54 < .001*** 
Left Ventricular Ejection 
Fraction, mean (SD)    
 60.9 (3.8)    
NYHA class, n (%)      
    Class I  6 (7.9)    
    Class II  57 (75)    
    Class III  11 (14.5)    
    Class IV  2 (2.6)    
Month of HF, mean (SD)  35.7 (28.4)    
Type of HF, n (%)      
    Systolic HF  11 (14.5)    
    Diastolic HF  65 (85.5)    
      
Note.   HRT= Estrogen replacement therapy; NYHA=New York Heart Association; HF=heart 
failure; Values are expressed as number (%). Percentage is expressed as valid percentage, 
which excludes missing data 





Table 3.4. Mean, Standard Deviation, and Group comparison for CogState tests  
 
 HF 










     
   Detection, speed
a
                 2.7 (0.1) 2.6 (0.1)   7.6 0.007 
   Identification, speed
a
  2.7 (0.1) 2.7 (0.0)   0.2 0.65 
   One Back, accuracy
b
 1.0 (0.2) 1.1 (0.1)   4.3 0.04* 
   International Shopping List, total
b
 20.2 (5.7) 23.4 (4.4) 14.7 < .001*** 
   International Shopping List, delayed recall
b
 6.8 (2.8) 8.3(1.9) 13.9 < .001*** 
  One Card Learning, accuracy
b
 0.9 (0.1) 0.9 (0.1)   3.6 0.06 






  2.8 0.10 
     
 
Note.  HF=heart failure  
Note.   *P < .05   **P <.01     ***P< .001 
a
Lower score=better performance.  
b
Higher score=better performance.  
c





Table 3.5.  Principal Components Analysis of  CogState Tests in the HF Group (n=76) 
 
 Factor loadings  
 Factor 1   Factor 2 
Factor 1: Memory   
      One Back, accuracy  0.81 -0.08 
      International Shopping List, total  0.71  0.27 
      International Shopping List, delayed recall  0.77  0.24 
      One Card Learning, accuracy  0.74 -0.39 
      Continuous Paired Associate Learning, error  0.61  0.07 
Factor 2 : Speed   
Detection task  -0.03  0.90 
Identification task  -0.05  0.91 
   
               Eigenvalue   3.15   1.38 
               Explained variance 44.95 19.69 
               Cumulative variance 44.95 64.64 
   
Total CogState tests   
Note.  HF=heart failure ; Kaiser–Meyer–Olkin (KMO) test measure of sampling adequacy = 
0.724; Bartlett’s test of sphericity P < .001 







Table 3.6  Pearson’s Product-moment Correlations Between CogState Tests and MoCA. 
 
CogState  Tests MoCA 
 HF group Healthy group Totals 
Detection task -0.186 0.017 -0.208* 
Identification Task  -0.208 -0.115 -0.191* 
One Back Task  0.417***  0.526***  0.472*** 
International Shopping List Task   0.565***  0.582***  0.610*** 
International Shopping List Task: Delayed 
recall 
 0.640***  0.647***  0.676*** 
One Card Learning Test   0.395***  0.330**  0.404*** 
Continuous Paired Associate Learning Task -0.396** -0.408** -0.421*** 
    
Note.   MoCA =Montreal Cognitive Assessment; HF=heart failure 























































Figure 3.1.Mean and Standard Deviation for CogState Tasks. HF=Heart Failure; DET= 
Detection task; IDN= Identification task; OBK= One Back Task; ISLT= the International 
Shopping List Task, total; ISLT-DR= the International Shopping List Task, delayed recall; 
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Menopausal Symptoms and Memory Performance in Women with Heart Failure 
Abstract 
Background: Memory deficits have been found in heart failure (HF) patients, but little is known 
about whether these are associated with menopausal symptoms in women with HF. 
Objectives: The aims of this study were to examine type, frequency, and severity of menopausal 
symptoms in women with HF, compared with healthy participants, and to explore the association 
between menopausal symptoms and memory performance among Taiwanese postmenopausal 
women with HF. 
Design: A cross-sectional, correlational study design was used. 
Participants and settings: A total of 140 participants (76 women with HF and 64 healthy 
women) were recruited from an academic medical center in Taiwan. 
Methods: Measures of demographic variables, menopausal symptoms, HF severity symptoms, 
global cognitive function, and memory were collected by self-report for women with HF. 
Clinical variables were obtained from medical records.  
Results: Women with HF had significantly higher scores for total menopausal symptoms and 
subscales for psychological (anxiety and depression), somatic, and vasomotor symptoms 
compared with healthy women. The most prevalent symptoms in women with HF were 
forgetfulness, backache, waking up during the night, and feeling tired or lacking in energy. 
Verbal memory was significantly correlated with anxiety and sexual symptoms; visual memory 




observed between memory performance and depressive, somatic, and vasomotor symptoms after 
adjustment for age, years of education, and comorbidity.  
Conclusion: This study demonstrated that menopausal symptoms were worse in women with HF; 
anxiety and sexual symptoms were associated with memory function. Future prospective studies 
are needed to evaluate associations between menopausal symptoms and memory function.  
Key words: Heart failure, Memory, Menopausal symptoms, Women 
 










1.  Introduction 
        Heart failure (HF) is a significant health problem worldwide.  The aging population and 
improvement in treatment of cardiovascular disease have contributed to both the increasing 
incidence and prevalence of HF (Lund & Mancini, 2004). Almost 46% of HF patients are 
women. Women with HF have more hospital discharges and longer hospitalizations than men, 
leading to increased costs of treatment (Roger et al., 2012; Frazier et al., 2007). Moreover, 
women tend to develop HF later in life and live longer after its onset (Adams et al., 1999; Frazier 
et al., 2007; Stromberg & Martensson, 2003). Taiwan's population is rapidly aging and the 
proportion of women has increased among elderly patients with HF (Tseng, 2011). The 
increasing prevalence of HF in Taiwan will likely be a significant burden for coming decades 
(Chen, Chen, & Tang, 2007).  
        In Taiwan, the mean menopausal age is between 48 and 50 years (Chow, Huang, & Lee, 
1997; Fuh, Wang, Lu, Juang, & Chiu, 2001). Menopausal symptoms may occur in 
premenopausal, perimenopausal, or postmenopausal women (Blümel et al., 2012). It is well 
known that these symptoms have a negative effect on quality of life (Karaçam & Seker, 2007). 
They include vasomotor, physical, psychological, and urogenital atrophy symptoms (Greene, 
1998). The types and severity of these symptoms vary by individual. Menopausal symptoms 
result from reduced estrogen because of decreased ovarian activity after menopause (Lokken & 
Ferraro, 2006; Rahman, Zainudin, & Mun, 2010). Previous research has demonstrated 
associations between endogenous hormone levels and menopausal symptoms. For example, 
vasomotor symptoms were associated with lower estradiol levels and hot flushes among women 
during the menopause transition (odds ratio =.77, p < 0.001) (Guthrie, Dennerstein, Taffe, Lehert, 




during the menopausal transition and early postmenopause (p = < 0.0001) (Woods, Mitchell , & 
Smith-Dijulio, 2010). Increasing estradiol levels by estrogen therapy (ET) improved depression 
among perimenopausal women (r = −0.68, p = 0.001) (Joffe et al., 2011). Most studies of 
menopausal symptoms have enrolled healthy women. In a literature review no studies were 
found on menopausal symptoms among women with HF.  
        The estrogen decline that accompanies menopause is thought to play a role in memory 
function after menopause. Studies indicate that estrogen affects the central nervous system 
through a variety of mechanisms to influence memory by elevating neurotransmitter levels, 
enhancing neuronal growth and synaptic plasticity, reducing cell apoptosis, and producing 
antioxidant properties (Craig & Murphy, 2007; McClure, Barha, & Galea, 2013; McEwen, 2002). 
It may be associated with multiple sites of estrogen receptors in the brain, including the 
hippocampus and prefrontal cortex, the brain regions involved in episodic and working memory 
(Ancelin & Ritchie, 2005). Episodic memory function concerns encoding and retrieving of 
conscious experiences from a person’s past. The core brain region for the episodic memory 
system depends upon the medial temporal lobes, including the hippocampus (Budson, 2009). 
Working memory refers to capacity to store information for intervals of several seconds to a 
minute (Cown, 2008; Nichols, Kao, Verfaellie, & Gabrieli, 2006). The prefrontal cortex is the 
primary neural substrate responsible for working memory tasks (Budson, 2009). 
        The influence of estrogen decline on memory performance has been demonstrated. Pre-
menopausal women who underwent oophorectomy and hysterectomy experienced significant 
decreases in memory tasks and had greater declines in verbal memory tasks with a greater than 
50% decrease in estradiol level post-surgery (Nappi et al., 1999). Other studies have also 




healthy postmenopausal women (Wroolie et al., 2011; Maki, 2012). Studies have shown that 
endogenous estrogen has a positive association with verbal memory in healthy postmenopausal 
women.  One study found that older women within the lowest estradiol tertile were two times 
more likely than women in the highest tertile to decline on verbal memory tasks (28% versus 
12%, p=0.004) (Yaffe et al., 2007). Others reported that high estradiol levels were related to 
better delayed verbal memory in healthy older women (Drake et al., 2000; Wolf & Kirschbaum, 
2002). Although memory functions are particularly influenced by hormones, no prior studies 
have evaluated the relationship between menopausal symptoms, which may reflect the 
decreasing estrogen levels, and memory in HF population. 
Evidence supports the biological hypothesis that HF has an adverse effect on memory 
performance. There are neurobiological changes and brain abnormalities that occur in the 
hippocampus in HF, which may affect memory functioning (Gruhn et al., 2001; Kumar et al., 
2009; Vogels, Flier, et al., 2007; Vogels, Oosterman, van Harten, Gouw, et al., 2007; Woo, 
Kumar, Macey, Fonarow, & Harper, 2009). In one study with 251 veteran outpatients with HF, 
researchers reported verbal learning, immediate memory, and delayed verbal memory were most 
impaired (Hawkins et al., 2012). Vogels, Oosterman, van Harten and Scheltens, et al. (2007) 
assessed memory among 62 HF outpatients, 53 age-matched cardiac controls and 42 age-
matched healthy controls. Extensive memory deficits in the HF group were found in verbal 
memory (delayed and immediate) compared with the other two groups. The scores for visual 
memory (immediate and delayed recall) were decreased on the Pattern Recognition Task in 62 
outpatients with HF, although the difference did not reach significance (p< 0.05). Recently, 
another study reported that twenty-three percent of 249 HF patients had impaired scores on 




patients had poor verbal memory and New York Heart Association (NYHA) Class was 
significantly associated with total recall score (Pressler et al., 2010a).   
Studies have reported differences between men and women on cognitive screening 
questionnaires in the HF population. One study reported women with HF (n = 836) had an 
increased probability of cognitive impairment compared to men (n =747) as assessed by the 
Hodkinson Abbreviated Mental Test (Zuccala et al., 2001). Researchers found more frequent 
abnormal scores in cognitive testing in women than men (n =360, 27.5% women) using the 
Pfeiffer Test (15.2% vs. 5%, p=0.003)  (Altimir et al., 2005). Moreover, a recent study with 50 
HF patients and 50 healthy control subjects reported that female gender was associated with 
poorer memory performance on tasks of early recall, and delayed recall compared to men (Sauvé 
et al., 2009). These results raise questions as to whether menopause-related estrogen loss may 
magnify memory deficits in women with HF.   
In summary, despite that emerging evidence suggests that HF has an adverse effect on 
memory performance and that high pre-menopausal estrogen concentrations in women are 
thought to be protective against memory loss, it is unknown whether the effects of estrogen 
decline after menopause as measured by menopausal symptoms are related to memory deficits in 
postmenopausal women with HF. To date, there has been no published evidence regarding 
menopausal symptoms and their relationship to memory performance in women with HF. 
Therefore, the primary aim of this study was to examine the type, frequency, and severity of 
menopausal symptoms in women with HF, compared with healthy participants. The secondary 
aim was to examine the association between menopausal symptoms and memory function among 
Taiwanese postmenopausal women with HF. Hypotheses were (1) Taiwanese postmenopausal 




matched healthy women; and (2) menopausal symptoms are related to memory performance 
among postmenopausal women with HF. 
2. Method 
2.1  Design and Procedures 
        A cross-sectional, correlational study design was used for the current study. Patients were 
recruited from the Tri-Service General Hospital in Taipei, Taiwan from November 2010 to 
October 2011. HF patients were recruited from cardiovascular clinics and healthy participants 
were recruited from outpatients of the gynecology clinic, the women’s health center, and 
volunteers in the same hospital.  The study was performed after approval from the Institutional 
Review Board of the University of Michigan and the Tri-Service General Hospital. Eligible 
participants referred through physicians were invited to participate in the study. During face-to-
face interviews at the clinics, informed consent was obtained from all participants by the 
investigator before data collection. Baseline data, including demographic and clinical items, 
menopausal symptoms, HF severity, and global cognitive function, were collected by the 
investigator using questionnaires and medical records reviews. After baseline data collection, 
computerized neuropsychological tests were administered by the investigator. Participants were 
not required to have prior computer experience to take the computerized tests. The time required 
to obtain and collect data was approximately 60 to 90 minutes. 
2.2 Sample 
        Eligibility criteria for women with HF included having a diagnosis of HF for at least 6 
months, natural menopause defined as last menstrual cycle completed longer than 12 months 
previously, age 50 years and older; and able to read and speak Mandarin. Eligibility criteria for 




the last three criteria listed above, as for HF patients.  Women were eligible for the healthy group 
if they had hypertension with blood pressure less than 140/90 mmHg or hyperlipidemia with 
cholesterol less than 200 mg/dl. Women were excluded from the two groups if they had 
conditions that may cause cognitive deficit (e.g., history of neurological disease, stroke, history 
of recurrent mental disorders, encephalopathy or impaired sensory problems (e.g., hearing loss 
and visual problems). 
2.3   Measures 
2.3.1. Postmenopausal symptoms associated with estrogen decline 
        Postmenopausal symptoms associated with estrogen decline were measured using the 
Greene Climacteric Scale (GCS). The GCS consists of 21 items, self-reported, divided into the 
following subscales: vasomotor
 
symptoms such as hot flushes and night sweats (2 items); 
psychological
 
symptoms such as anxiety and depressive symptoms (11 items); somatic 
symptoms (7 items); and loss of interest in sex (1 item) (Greene, 1998). Each symptom is rated 
by participants from 0 to 3 (0= not at all; 1=a little; 2=quite a bit; 3= extremely).
 
Construct 
validity was supported in a previous study; internal consistency reliability of the GSC subscales 
ranged from 0.72 - 0.91 (Chen, Davis, Wong, & Lam, 2010; Greene, 1998). The GCS was 
translated to Chinese by two Taiwanese with Masters’ degrees in Nursing. The Chinese version 
of GCS was translated back into English by a bilingual translator. The consistency of the back-
translated English version and original version was evaluated by the research team (Pai, 2002). 
The construct validity and reliability of the Chinese version of the GCS were supported in 
postmenopausal women.  Cronbach's alphas for the GCS-C were 0.86 - 0.92, and the correlation 
of test-retest reliability (at 2 weeks) was 0.92 (Fang, 2005; Liu, 2007; Pai, 2002). An additional 




including cold sweats (night or day), waking up during the night, vaginal dryness, backache, and 
forgetfulness (Chow et al., 1997; Fu, Anderson, & Courtney, 2003). Scores range from 0 to 78, 
with higher scores indicating more symptoms or more severe symptoms. The internal 
consistency reliability (Cronbach’s alpha) for the present study was 0.90. 
2.3.2. HF severity 
        Heart failure severity was assessed by the measure of perceived functional capacity, the  
NYHA functional classification and the Duke Activity Status Index ( DASI)  (Hlatky et al., 1989; 
New York Heart Association Criteria Committee, 1964). NYHA class was measured and 
confirmed by patients’ physicians in outpatient clinics before the interview. Patients are assigned 
to
 
1 (no symptoms of HF upon ordinary physical activity) to 4 (symptoms of HF
 
at rest) (New 
York Heart Association Criteria Committee, 1964). The validity and reliability of the NYHA 
classes were reported (Bennett, Riegel, Bittner, & Nichols, 2002).  The DASI consists of 12 
items that assess whether participants can perform daily activities with a 4-point scale. In a 
previous study among 50 subjects undergoing exercise testing, it significantly correlated with 
peak oxygen uptake in development (r = 0.81, p<0.0001) and validation phases (r = 0.81, 
p<0.001) (Hlatky et al., 1989). Possible weighted scores range from 0 to 58.2. Higher scores 
represent better perceived functional capacity. The reliability coefficient of the DASI score was 
satisfactory (Cronbach's α =0.87) in 249 HF patients (Pressler et al., 2010b).
 
This questionnaire 
has been validated in the Chinese language (Chen, 2001). The Cronbach’s alpha in this study 
was 0.69.  
2.3.3. Global cognitive function 
        Global cognitive function was measured using the Montreal Cognitive Assessment (MoCA) 




series of thirteen tests: visuospatial abilities; naming; memory; attention task; language; verbal 
abstraction tasbk; delayed recall; and orientation. The score of the MoCA ranges from 0 to 30, 
with higher scores indicating better global cognitive function. Validity and reliability were 
supported in previous study. The test-retest reliability was 0.92 at 35 days; the Cronbach's alpha 
for internal consistency was 0.83. In the original study among 94 patients with mild cognitive 
impairment (MCI), 93 patients with mild Alzheimer’s disease (AD), and 90 healthy elderly, the 
MoCA had excellent sensitivity in identifying MCI and AD (90% and 100%) and normal elderly 
were identified with a specificity of 87% by using a cutoff score of 26 (Nasreddine et al., 2005). 
Criterion and concurrent validity were satisfactory for the Chinese version of MoCA. The 2-
week test-retest reliability and inter-rater reliability were 0.96 and 0.87. In a study carried out in 
Hong Kong, the Cronbach’s alpha for internal consistency was 0 (Wong et al., 2009). Using an 
optimal cut-off score of 23/24 in a Taiwanese population, sensitivity and specificity for MCI 
were 92% and 78%, respectively (Tsai et al., 2012). 
3.4. Memory deficits 
        Memory deficits were measured using the CogState battery, a valid and reliable 
computerized neuropsychological test battery that is sensitive in detecting decline over time in 
older adults (Cysique, Maruff, Darby, & Brew, 2006; Darby, Maruff, Collie, & McStephen, 
2002). The CogState Battery is standardized and easy to administer; scoring is completed within 
the program. Six different tests from the computerized cognitive battery considered to evaluate 
memory and other cognitive abilities are presented in Table 4-1, with detail available in previous 
publications (Darby et al., 2002; Harel et al., 2011; Lim, Peitrzak, Snyder, Darby, & Maruff, 
2012). The test-retest reliability was supported in 263 older adults at 3-month intervals during 12 




(Lim et al., 2012). The CogState battery demonstrated good sensitivity (78%) and specificity 
(90%) for mild cognitive impairment (MCI) (De Jager, Schrijnemaekers, Honey, & Budge, 
2009).  
         Working memory was measured by the One Back Task (OBK). In the OBK, a card is 
presented in the center of the screen. The participant must indicate whether the new card is the 
same or different to the previously presented card when the card changes (Cysique et al., 2006). 
This task assesses accuracy of performance.  
        Episodic memory was assessed by verbal and visual stimuli. The International Shopping 
List Task (ISLT) and the International Shopping List Task-Delayed Recall (ISLT-DR) were used 
to measure verbal immediate and delayed memory. The test consists of immediate free recall for 
a series of 12-word lists for three consecutive trials (trials 1-3), followed by recall for the word 
list after a 20-minute delay (trial 4). The range of correct scores is 0-36 in ISLT and the range of 
correct scores is 0-12 in ISLT-DR. The One Card Learning Task (OCL) and the Continuous 
Paired Associate Learning Task (CPAL) were used to assess visual memory. In the OCL, the 
participants were instructed to respond “Yes” if the card has appeared before or “No” if it has not 
appeared (Fredrickson et al., 2010). This task assesses accuracy of performance. For the CPAL, 
the participants were asked to determine whether a single picture presented in the center of the 
screen was the same as any one of the pictures presented in peripheral locations and tap the same 
one in the peripheral location (O'Donnell, Pietrzak, Ellis, Snyder, & Maruff, 2011). It is scored 
as the total number of errors across five rounds, with a lower score reflecting better visual 
memory performance. 
Speed of performance was computed as the mean of the log10 transformed reaction times 




computed as the arcsine transformation of the proportion of correct responses for total trials 
(Fredrickson et al., 2010; Maruff et al., 2009). Higher scores indicate better performance. The 
total number of words recalled in 3 trials, the number of words recalled after 20 minutes for 
ISLT, and total number of errors for CPAL were computed for analysis. 
2.3.5. Demographic and clinical variables 
        Data were collected for demographic and clinical information (age, race, education, marital 
status, employment status, and blood pressure), and menopausal history (age when menstruation 
began, number of pregnancies, number of live births, age at menopause, duration of menopause, 
hysterectomy and ovariectomy, and estrogen replacement therapy). For HF participants, data 
were also collected for number of comorbid conditions and HF-related variables (i.e., LVEF, 
NYHA class, heart failure duration, and type of HF).  
2.4    Statistical analyses         
        Descriptive statistics were used to compare demographics, clinical variables, and study 
variables among the HF and healthy groups of women. Categorical variables were examined 
using chi-square and Fisher’ exact tests; continuous variables were examined using independent 
t-tests. To achieve aim one, means, medians, frequencies and standard deviations were calculated 
to describe the frequency and severity of postmenopausal symptoms associated with estrogen 
decline in the HF group. Independent t-tests were used to compare scores of menopausal 
symptoms between the HF and healthy groups.  
        To achieve aim two and test the hypothesis that menopausal symptoms are related to 
memory performance among postmenopausal women with HF, Pearson product-moment 
correlation coefficients were used to assess multicollinearity among explanatory variables and 




OCL, CPAL). A series of simultaneous multiple regression analyses were performed separately 
to explore the association between postmenopausal symptoms and memory adjusted for 
covariates.  Regression diagnostics were carried out to test the assumptions underlying 
regression analysis (independence, normal distribution, linearity, homoscedasticity).
 
In the 
different series, the symptom scores (which included scores for, anxiety symptoms, depressive 
symptoms, somatic symptoms, vasomotor symptoms, and sexual symptoms) were entered as the 
explanatory variables and each memory test was entered as the dependent variable in separate 
equations to examine memory domains in HF group. Age, years of education, and comorbid 
conditions were entered as covariates because they may influence memory performance (using 
the significance level P < .05). All analyses were conducted using SPSS version 17. 
3. Results 
3.1 Characteristics of the sample 
       Characteristics of the study participants are presented in Table 4-1.  A total of 140 women 
were recruited in this study. Seventy-six postmenopausal women were in the HF group and 64 
postmenopausal women were in the healthy group. The mean age of the sample was 69.4 years 
old (SD=8.9). There was no significant difference between the groups with respect to age, 
marital status, years of education, whether living alone or not, and diastolic blood pressure. In 
addition, menopausal variables including age at menopause, duration of menopause, ever taking 
HRT, and taking HRT now did not differ between the groups.  Compared to healthy women, 
women with HF were less often employed, had higher systolic blood pressure, more comorbid 
conditions, worse functional capacity, and poorer global cognitive function. Most of the women 
with HF had diastolic HF and were NYHA class II.   




        Scores for total GCS and its subscales for both groups are presented in Table 4-2. The total 
GCS score with 21 items or 26 items was significantly greater in women with HF (p <.001), 
indicating higher severity of menopausal symptoms in this group. Women with HF also had 
significantly higher scores on subscales for psychological (p <.001), somatic (p <.001), and 
vasomotor (p <.001) symptoms. The scores for sexual symptoms were higher in women with HF 
compared with the healthy women, but the difference did not reach significance. Hypothesis one 
was supported in the study. 
        In Table 4-3, mean scores and frequencies for the 21 GCS items, and additional 5 items for 
menopausal symptoms,  are presented for women with HF. Results showed that the highest 
scores were reported for waking up during the night (1.56 + 0. 96), backache (1.37 + 0.88), 
forgetfulness (1.20+ 0.69), and muscle and joint pain (1.17 + 0.99). Thirteen of 26 menopausal 
symptoms had a prevalence of ≥ 50%.  Of the 26 symptoms comprising the scale the most 
prevalent were: forgetfulness (88.2%), backache (85.5%), waking up during the night (84.2%), 
and feeling tired or lacking in energy (69.7%). 
3.3 Association between menopausal symptoms and memory in HF 
        In correlation analyses, the total score of the 21 GCS items was highly correlated with 
subscales of depressive and somatic symptoms (r =.88, p <.001; r =.89, p <.001). The total score 
for the 26 menopausal symptom items was also highly correlated with depressive and somatic 
symptoms (r =.88, p <.001; r =.89, p <.001). Psychological symptoms were highly correlated 
with anxiety and depressive symptoms (r =.89, p <.001; r =.87, p <.001). Therefore, total score 
for the 21 GCS items, total score for the 26 menopausal symptom items and psychological 
symptoms were not entered into multiple regression equations. The subscales of anxiety, 




equations. Vasomotor symptoms were significantly positively associated with ISLT (total recall, 
r =.25, p =.03). All other correlations between menopausal symptom variables and memory 
variables were not significant. 
        In regression models adjusted for age, education, and comorbidity, associations between 
GCS scores and CogState tasks in women with HF were explored. With regard to working 
memory, anxiety, depressive, somatic, vasomotor, and sexual symptoms were not significantly 
associated with OBK scores. Regarding verbal memory (Table 4-4), the anxiety (t = -2.21, p 
=.03)  and sexual symptoms (t = -2.39, p =.02) subscales were the variables to significantly 
account for ISLT-DR. Women with more anxiety and sexual symptoms had worse verbal 
memory (ISLT-DR). However, anxiety, depressive, somatic, vasomotor, and sexual symptoms 
did not influence ISLT (total recall). Regarding visual memory, sexual symptom (t = -2.59, p 
=.01) was associated with OCL. Having more sexual symptom was associated with poorer OCL 
performance. Moreover, anxiety symptoms (t = 2.95, p =.01) were significantly related to more 
errors in CPAL performance. The hypothesis two that menopausal symptoms (anxiety and sexual 
symptoms) are associated with memory performance (verbal and visual memory) was partially 
supported.  
4. Discussion 
        To our knowledge, this is the first study to examine menopausal symptoms and the 
association between them and memory performance in HF. Women with HF had significantly 
higher scores for total menopausal, psychological, somatic, and vasomotor symptoms than 
healthy women; women with HF also experienced higher severity of menopausal symptoms. 
Moreover, verbal memory and visual memory were significantly related to anxiety and sexual 




        In the current study, women with HF had higher scores for psychological, somatic, and 
vasomotor symptoms than the healthy group. These group differences were expected, as other 
investigators have found that severity of menopausal symptoms was related to health status 
(Gharaibeh, Al-Obeisat, & Hattab, 2010), chronic disease history (Shu, Luh, Li, & Lu, 2007), 
and cardiovascular disease risk factors (Cagnacci et al., 2012). Although the main cause of 
menopausal symptoms is related to estrogen deficiency, women in the present study had HF and 
more comorbidities that may contribute to the increased risk of severe menopausal symptoms. 
Observed differences also may be explained by measurement issues. Some HF symptoms were 
similar to menopausal symptoms, for example, difficulty in sleeping is both a menopausal and 
HF symptom.  The HF symptoms may have directly increased frequency and severity of 
menopausal symptoms measured by GCS and the 5 additional items.  As these symptoms have a 
negative effect on quality of life (Karaçam & Seker, 2007), future study is needed to differentiate 
menopausal and HF symptoms and develop a measure of menopausal symptoms that is suitable 
for women with chronic disease such as HF. 
        Earlier studies of cognitive function in HF have not reported relationships between 
menopausal symptoms and memory function. Our study found that some menopausal symptoms 
(such as anxiety and sexuality symptoms) accounted for performance on memory tasks in 
women with HF. Studies of the effect of estrogen therapy on cognitive function may provide 
insight into the association between menopausal symptoms and memory (Yaffe, Sawaya, 
Lieberburg, & Grady, 1998). In a meta-analysis study on the effect of HRT on cognitive decline 
in healthy postmenopausal women, investigators found that HRT improved verbal memory in 
women with menopausal symptoms, but there was no effect on asymptomatic women. The 




Janowsky, Chan, & Nelson, 2001). However, these studies did not directly examine the possible 
association between menopausal symptoms and memory. 
        Anxiety symptoms, one subscale of the psychological symptoms, were associated with 
lower memory function in women with HF, as seen in other populations (Andreoletti  et al., 2006; 
Smeets, Otgaar, Candel, & Wolf, 2008; Wetherell, Reynolds, Gatz, & Pedersen, 2002). The 
relationship of anxiety symptoms to memory has not been often examined in patients with HF. A 
possible mechanism for the association is that psychological distress leads to increased cortisols 
level through activation of the hypothalamus-pituitary adrenal (HPA) axis (Wolf, 2009). A 
functional magnetic resonance imaging (fMRI) study revealed that increased cortisol impaired 
memory retrieval by reduced activation in the hippocampus (Oei et al., 2007). Future prospective 
studies are needed to evaluate the association between measures of anxiety and memory 
performance among women with HF. 
        Our observations of negative relationships between sexual symptoms and both verbal and 
visual memory have not been reported previously.  Although sexual desire may not have a direct 
central effect on memory and the mechanisms by which it affects memory performance are 
unknown, previous studies have reported that decreasing estrogen levels were correlated with 
decreasing sexual desire (Woods et al., 2010; Woods et al., 2007). The association between 
sexual symptoms and memory may reflect decreasing estrogen levels. In addition, experiencing 
symptoms of hot flashes, fatigue, depressed mood, anxiety, and sleep problems have been 
significantly associated with lower sexual desire (Woods et al, 2010). Women with HF in our 
study showed more symptoms compared with healthy women. The effect of sexual desire on 
memory may be influenced by other symptoms. Future studies should explore relationships 




                In our study, no direct association was found between depressive, somatic, vasomotor 
symptoms and memory function. Similar results were found in some studies that examined 
memory and other perceived symptoms, such as depression (Mauro et al., 2006; Sauvé et al., 
2009; Pressler et al., 2010a) and health-related quality of life (Pressler et al., 2010b). One 
possible explanation suggested by past research is that the objective memory measures do not 
correlate strongly with subjective measures (Pressler et al., 2010b). In addition, the low level of 
depressive symptoms (mean=0.65), somatic symptoms (mean=0.77), and vasomotor symptoms 
(mean=0.44) might not have been great enough to have an influence on memory performance in 
this sample.  
        Contrary to expectation, menopausal symptoms were not related to any tasks for working 
memory, indicating that working memory was fairly resistant to or independent of them in this 
sample of women with HF. It is well known that estrogen affects memory through the broader 
distribution of estrogen receptors in brain areas such as the hippocampus and neocortex, the 
brain regions involved in episodic memory and working memory (Ancelin & Ritchie, 2005). 
However, our findings support those of other studies. Past investigations examined effects of 
endogenous and exogenous estrogen exposures in postmenopausal healthy women and did not 
find associations between estrogen measures and working memory tasks, such as digit span 
backwards, Letter-Number Sequencing and serial subtraction of sevens and spelling WORLD 
backward (Henderson & Popat, 2011). Possible explanations are that circulating estrogen levels 
may not be suitable measures to use to predict neural effects on the brain (Henderson & Popat, 
2011).   
        Furthermore, the mean age of women with HF in our study was 69.7 (SD=10.2). Findings 




(Espeland et al., 2004). The effect of estrogen on the aging brain may be different than that on 
brains of younger individuals; the association between menopausal symptoms and related 
estrogen decline and memory might vary by age. Future studies need to include younger women 
with HF to clarify the relationship between menopausal symptoms and memory. 
5. In conclusion 
        Results of this study suggest that menopausal symptoms were worse in women with HF 
compared to healthy women, and that anxiety and sexual symptoms were associated with poorer 
verbal and visual memory function. This study has limits in terms of its ability to differentiate 
menopausal and HF symptoms, and its ability to capture actual estrogen decline. Future studies 
should develop a suitable tool to evaluate menopausal symptoms in women with HF and collect 
serum estrogen concentrations in order to establish whether self-reported menopausal symptoms 
are reflected in actual estrogen concentrations. In addition, results are not generalizable to 
women with HF with other menopausal status or disease. Prevalence of postmenopausal women 
with HF is increasing. Health professionals need to be aware  that  women with HF who have 
more menopausal symptoms may be most at risk for memory deficits, develop interventions to 
treat symptoms and memory deficits, and assess whether their self care abilities are compromised. 
Future prospective studies are needed to evaluate associations between menopausal symptoms, 
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Age, mean (SD) 69.4 (8.9) 69.7 (10.2) 68.9 (7.1) t=0.53 0.59 
    Race, n (%)    Fisher’s 
exact test 
0.02* 
    Taiwanese 104 (74.3) 49 (64.5) 55 (85.9)   
    Mainland China     26 (18.6) 19 (25) 7 (10.9)   
    Hakka 8 (5.7) 6 (7.9) 2 (3.1)   
    Aborigine      2 (1.4) 2 (2.6) 0 (0)   
Marital status, n (%)                                Fisher’s 
exact test 
0.16 
    Married 102 (72.9) 61 (80.3) 41 (64.1)   
    Single  3 (2.1) 1 (1.3) 2 (3.0)   
    Divorced 6 (4.3) 2 (2.6) 4 (6.3)   
    Widowed 29 (20.7) 12 (15.8) 17 (26.6)   
Education, mean (SD)                              7.6 (3.2) 7.3 (3.3) 8.0 (3.1)    t=-1.31 0.19 
Employment, n (%)                                              χ
2
=11.25 0.001** 
    No 115 (82.1) 70 (92.1) 45 (70.3)   
    Yes 25 (17.9) 6 (7.9) 19 (29.7)   
Live alone, n (%)                                χ
2
=1.28 0.52 
    No 115 (82.1) 64 (84.2) 51 (79.7)   
    Yes 25 (17.9) 12 (15.8) 13 (20.3)   
Systolic blood pressure, 
mean (SD) 
129.5 (15.8) 135.5 (17.5) 122.3 (9.5) t=5.34 < .001*** 
Diastolic blood pressure, 
mean (SD) 
75.3 (8.9) 76.1 (10.2) 74.4 (6.9) t=1.1 0.27 
Comorbidity number, 
mean (SD) 
1.1 (1.0) 1.8 (0.9) 0.2 (0.4) t=12.16 < .001*** 
Age at menopause,  
mean (SD) 
50.0 (5.1) 50.4 (5.8) 49.6 (4.1) t=0.83 0.407 
Months since 
menopause, 
 Mean (SD) 
232 (116) 232 (133) 231 (94) t=0.08 0.929 
Ever take HRT, n (%)    χ
2
=0.00 0.983 
     No 95 (67.9) 51 (67.1) 44 (68.8)   
     Yes 43 (30.7) 23 (30.3) 20 (31.2)   
Take HRT now, n (%)    Fisher’s 
exact test 
0.12 
     No 136 (97.1) 72 (94.7) 64 (100)   
     Yes 4 (2.9) 4 (5.3) 0 (0)   
MoCA, mean (SD) 26.2 (3.3) 25.1 (3.7) 27.5 (2.1) t=-4.54 < .001*** 
 Duke Activity Status 
Index,mean (SD) 











The Greene Climacteric 
Scale, mean (SD) 
14.6 (9.5) 17.9 (10.4) 10.8 (6.8) t=4.69 < .001*** 
Left Ventricular Ejection 
Fraction, mean (SD)    
 60.9 (3.8)    
NYHA class, n (%)      
    Class I  6 (7.9)    
    Class II  57 (75)    
    Class III  11 (14.5)    
    Class IV  2 (2.6)    
Month of HF, mean (SD)  35.7 (28.4)    
Type of HF, n (%)      
    Systolic HF  11 (14.5)    
    Diastolic HF  65 (85.5)    
      
Note.   HRT= Estrogen replacement therapy; MoCA= Montreal Cognitive Assessment; 
NYHA=New York Heart Association; HF=heart failure; Values are expressed as numbers (%). 
Percentage is expressed as valid percentage, which excludes missing data  





Table 4.2.  Scores for Subscales and Total Greene Climacteric Scale for Two Groups 







Subscales in GCS     
Psychological (items 1-11; range 0-33)                 6.96 (4.95)   4.02 (3.36) 4.04 < .001*** 
    Anxiety (items 1-6; range 0-18)                   3.71 (2.75)   2.42 (2.22) 3.01  0.003** 
    Depressive (items 7-11; range 0-15)                 3.25 (2.77)   1.59 (1.71) 4.12 < .001*** 
Somatic (items 12-18; range 0-21)                   5.42 (4.15)   2.73 (2.44) 4.56 < .001*** 
Vasomotor (items 19-20; range 0-6)                 0.88 (1.14)   0.52 (0.89) 2.08  0.039* 
Sexual (item 21; range 0-3)                   0.30 (0.80)   0.13 (0.42) 1.60  0.112 
     
Total score (items 1-21; range 0-63) 13.54 (9.29)   7.39 (5.56) 4.64 < .001*** 
Total score (items 1-26; range 0-78) 17.95 (10.40) 10.82 (6.81) 4.69 < .001*** 
Note.   *P < .05   **P <.01     ***P< .001; GCS= the Greene Climacteric Scale; Per item score 



































Table 4.3. Mean Scores for the Greene Climacteric Scale and Five Additional Items in Women 
with HF 
 Women with HF (n=76)        
Mean ± SD (%) 
Heart beating quickly or strongly 0.62 ± 0.77 (48.4) 
Feeling  tense or nervous 0.70 ± 0.80 (53.9) 
Difficulty in sleeping 0.96 ± 1.06 (53.9) 
Excitable 0.32 ± 0.62 (23.7) 
Attacks of panic 0.41 ± 0.73 (28.9) 
Difficulty in concentrating 0.71 ± 0.78 (53.9) 
Feeling tired or lacking in energy 0.96 ± 0.81 (69.7) 
Loss of interest in most things 0.64 ± 0.80 (47.4) 
Feeling unhappy or depressed 0.63 ± 0.75 (51.3) 
Crying spells 0.36 ± 0.65 (26.3) 
Irritability 0.66 ± 0.81 (50.0) 
Feeling dizzy or faint 0.74 ± 0.84 (52.6) 
Pressure or tightness in head or body 0.67 ± 0.85 (46.1) 
Parts of body feel numb or tingling 0.82 ± 0.89 (52.6) 
Headaches 0.50 ± 0.72 (39.5) 
Muscle and joint pain 1.17 ± 0.99 (68.4) 
Loss of feeling in hands or feet 0.93 ± 0.88 (63.2) 
Breathing difficulties 0.59 ± 0.73 (46.1) 
Hot flushes/sudden warmth 0.41 ± 0.64 (34.2) 
Sweating night or day 0.47 ± 0.74 (34.2) 
Loss of interest in sex 0.30 ± 0.80 (15.8) 
Five additional items:  
Cold sweats (night or day) (item22)                 0.28 ± 0.60 (21.1) 
Waking up during the night (item23)                 1.56 ± 0.96 (84.2) 
Vaginal dryness (item24)                 0.37 ± 0.71 (26.3) 
Forgetfulness (item25)                 1.20 ± 0.69 (88.2) 
Backache (item26)                 1.37 ± 0.88 (85.5) 
Note. Per item score range 0 to 3; higher score in the Greene Climacteric Scale = the higher 

















Note: Linear regression analysis adjusted by age, years of education, and comorbidity; HF=Heart 
Failure; ISLT-DR= the International Shopping List Task, delayed recall; OLT= One Card 
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 = .34, F=4.86,  p <.0001  
           Table 4.4. Multiple Regression Analysis: Explanatory Variables of the Greene Climacteric 
Subscales  for Memory Performance in Women with HF  
Models Variable B SE B Beta t P value 
       
ISLT-DR
 a
 Anxiety symptoms -.24 .11 -.23 -2.21 .03 
 Depressive symptoms .23 .14 .22 1.67 .10 
 Somatic symptoms -.16 .09 -.23 -1.84 .07 
 Vasomotor symptoms .46 .25 .18 1.86 .07 
 Sexual symptom -.75 .32 -.21 -2.39 .02 
       
OCL
 b
 Anxiety symptoms .00 .01 .00 -.02 .98 
 Depressive symptoms .00 .01 -.04 -.19 .85 
 Somatic symptoms .01 .01 .18 1.01 .32 
 Vasomotor symptoms -.01 .01 -.05 -.38 .71 
 Sexual symptom -.04 .02 -.32 -2.59 .01 
       
CPAL
c
 Anxiety symptoms 8.79 2.98 .38 2.95 .01 
 Depressive symptoms -6.11 3.83 -.25 -1.60 .12 
 Somatic symptoms 2.86 2.56 .18 1.12 .27 
 Vasomotor symptoms -1.17 7.07 -.02 -.17 .87 
 Sexual symptom 12.96 9.37 .16 1.38 .17 
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Summary and Conclusion  
Summary 
        The primary purpose of the study was to examine memory performance among Taiwanese 
postmenopausal women with HF compared with age- and education-matched healthy control 
participants, and to evaluate factors that explain memory performance. In addition, it examined 
the validity of the Chinese Version of the CogState computerized cognitive assessment battery in 
HF group. Finally, it focused on menopausal symptoms and their relationships to memory 
performance among Taiwanese postmenopausal women with HF. 
        The theoretical framework for the study links the neurobiological theory of HF, the 
biological theory of menopausal-related estrogen loss in post-menopausal women, and the 
neurobiological effects of estrogen to the neurobehavioral theory for memory functioning, 
specifically working memory and episodic memory. Cognitive deficits were examined using the 
CogState computerized cognitive assessment battery. 
        In Chapter II, hypothesis one was supported in this sample, Taiwanese postmenopausal 
women with HF had poorer working memory and episodic memory (verbal memory) 
performance than age- and education-matched healthy women participants. Verbal memory was 
the most affected domain in this population. Hypothesis two was partially supported. Age 
explained working memory; age, HF severity, comorbidity, and HF type explained verbal 
memory. However, postmenopausal symptoms associated with estrogen decline were not 




        Chapter III examined the psychometric properties of the Chinese Version of the CogState 
computerized cognitive assessment battery used in the study. The construct validity of the 
Chinese CogState tests was supported by significant correlations with MoCA, significant 
differentiation between patients with HF and healthy control groups, and an exploratory factor 
analysis that pointed to two factors of the CogState battery. Findings indicated that the Chinese 
version of the CogState battery is a valid instrument to assess cognitive performance among 
women with HF in Taiwan. 
        In Chapter IV, severity of menopausal symptoms in women with HF was examined as well 
as the association between menopausal symptoms and memory function. Hypothesis one was 
supported: women with HF had more severe menopausal symptoms on subscales for 
psychological, somatic, and vasomotor symptoms compared with age- and education-matched 
healthy women. Hypothesis two was partially supported. After adjustment for age, years of 
education, and comorbidity, verbal and visual memory were significantly associated with anxiety 
and sexual symptoms. However, scores for depressive, somatic, and vasomotor symptoms were 
not correlated with any CogState tasks. This study suggested that women with HF experienced 
worse menopausal symptoms and anxiety and sexual symptoms may have a negative influence 
on memory performance. 
        The findings of this study are significant to the scientific body of knowledge for several 
reasons. First, the findings of the study showed poorer memory performance in Taiwanese 
women with HF compared to Taiwan healthy women with matched age and education. This 
result was consistent with other studies conducted in western countries, suggesting HF disease 
may impair memory function regardless of culture and race.  Second, another important finding 




compared to healthy control women. Prior HF research in western populations with men and 
women also showed that working memory and verbal memory were common affected domains.  
The results of this study provide a better understanding of the memory performance focused on 
women population. Third, verbal memory was the most affected memory domain in women with 
HF compared to other memory domains. It would be important for future research to evaluate the 
nature of verbal memory problems and to find ways to reduce the impact of decreased verbal 
memory. Fourth, an unexpected finding was that HF type was an explanatory variable for verbal 
memory. Women with systolic HF had worse verbal memory compared to women with diastolic 
HF. The effect of HF type on verbal memory was still found even when controlling for 
covariates such as age, education, and number of comorbidities. This finding was worthy of 
notice because the majority of research in HF and cognition were conducted in patients with 
systolic HF, and no study explored memory performance in patients with diastolic HF. The HF 
type may appear to influence the memory performance in women with HF. However, sample 
size of women with systolic HF was small and further studies need to fully examine HF type. 
Strengths 
        This is the first study to investigate cognitive function, specifically working memory and 
episodic memory, in Taiwanese women with HF and explore factors associated with these 
deficits. Findings suggested that Taiwanese women with HF had poor memory performance 
compared to a healthy control group; results are similar to those from studies conducted in 
western countries. Moreover, this is the first study to validate the Chinese version of the 
CogState Computerized Cognitive Assessment Battery in Taiwanese patients with HF. This is 
also the first study to examine the relationship between menopausal symptoms and memory 




        One strength of the study is that potential covariates were controlled by study design and 
statistical methodology. The study design included an age- and education-matched healthy group. 
Moreover, potential covariates included in regression models, such as education, comorbidity, 
and HF type were selected based on literature review and statistical outcomes. 
        Another strength of the study is that a valid and reliable computerized neuropsychological 
test battery was used to assess specific domains of memory.  It is easy to administer and scores 
and is completed within the program, which made the battery useful in detecting memory change 
in clinical settings. 
        Furthermore, a strength is that the HF sample in this study are women and majority of them 
(85%) had diastolic HF. Compared to men, women tend to develop HF with preserved 
ventricular function (diastolic HF). Most past studies recruited patients with systolic HF, and it is 
not clear whether women with diastolic HF would have shown similar results. The finding 
indicated their performance was similar to those with systolic HF.           
Limitations 
        The study was limited in that it had a cross-sectional design. Information on long-term 
cognitive performance could not be obtained and the trajectory of memory performance could 
not be determined. In addition, test-retest reliability of the instruments was not ascertained since 
it used only one-time measures. 
        Another design-related limitation is that a control group with major chronic diseases other 
than HF was not included. Findings indicated that memory deficits were found in women with 
HF who often had comorbid disease such as uncontrolled hypertension or diabetes. However, it 
is not known whether the memory deficits were associated with these major medical conditions 




        An additional limitation of this study is that estrogen decline was measured by self-reported 
menopausal symptoms.  As menopausal symptoms are affected by other factors, they may not 
reflect actual estrogen condition. 
        Finally, participants in this study were recruited from a medical center in Taipei, Taiwan. 
The sample does not necessarily represent all women with HF in Taiwan. Future studies should 
recruit participants from multiple sites in Taiwan. 
Implications for future research 
       Longitudinal studies are needed to examine changes in memory performance in women with 
HF and to evaluate the factors that explain these memory changes. As mentioned above, a 
comparison group with medical conditions other than HF should be included in future studies to 
evaluate whether memory deficits are associated only with HF, or other major chronic diseases, 
as well. 
        Future studies should collect blood estrogen samples that can directly confirm the 
relationship between estrogen level and memory performance. In this study, although the total 
score of self-reported menopausal symptoms associated with estrogen decline was not related to 
memory performance, scores for subscales such as anxiety and sexual symptoms were 
significantly related. Future studies are needed to examine whether the estrogen levels could be a 
factor that influence memory function in postmenopausal women with HF.      
        Another recommendation is to compare memory performance in larger samples of patients 
with systolic and diastolic (preserved systolic function) HF. Interestingly, findings of this study 
showed that women with systolic HF had poor verbal memory compared to women with 




future study would contribute to knowledge regarding whether HF type impacts memory 
function.  
        Future research may further validate the Chinese version of the CogState battery by 
comparing it with a well-established standard neuropsychological test that provides a diagnosis 
of cognitive impairment. Stability of the instruments would also need to be established. 
         Future studies might also expand on the association between memory deficits and 
menopausal stages and younger women with HF. The sample in this study was postmenopausal; 
we did not recruit women with younger age, or women in pre- or peri- menopausal stages. These 
future studies would help to explore the possible factors that may explain memory deficits in 
women with HF. 
        Cognitive training interventions have been limited in the HF population. A preliminary 
study using nurse-enhanced cognitive training intervention demonstrated improved memory and 
conduct of daily activities in western patients with HF (Pressler et al., 2011). In that study, the 
nurses were not only interveners, but could monitor intervention adherence.  More nurse-
enhanced cognitive training interventions should be developed and modified for testing in 
Taiwanese women with HF.  
        Research on cognitive function and HF is still in development. As possible factors and 
mechanisms of memory change in HF are identified, more research is needed to fully explore the 
impact of memory declines on outcomes such as quality of life, self-care and daily activities, and 
mortality. 
        One last recommendation is to conduct direct evaluations of the influence of menopausal 
symptoms on patients’ quality of life outcomes. This study showed that women with HF reported 




symptoms would affect their actual quality of life. An examination will provide important 
information about the effects of menopausal symptoms on their living in women with HF. 
Moreover, intervention focusing on this vulnerable population should be developed to decrease 
their menopausal symptoms. 
Implications for nursing practice 
        The population has aged and the proportion of women has increased among elderly patients 
with HF not only in Taiwan, but also in the rest of the world. This study contributes to better 
understanding of memory deficit patterns in Taiwanese postmenopausal women with HF that is 
important to the provision of improved care and treatment. Sound memory is absolutely critical 
to adapting to illness, modifying one’s knowledge base needed to monitor health status, and 
being able to incorporate new self-care practices. If women with HF experience significant 
memory decline, their ability to adhere to complex medication schedules and dietary therapies 
may be compromised because of forgetfulness and poor learning ability (Dickson, Tkacs, & 
Riegel, 2007). Nurses are the primary care providers who frequently observe cognitive changes 
in patients over time as well as receive reports of memory changes from family members 
(Athilingam & King, 2007). Application of these findings can help Taiwanese nurses to assist 
women with HF in improving treatment adherence, self-care and living with HF. 
        Assessment: Memory deficits are common in women with HF; researchers in western 
countries have used a variety of neuropsychological tests in these patients. Many may not be 
feasible for use in nursing practice because they need special training to administer and score. 
The Chinese Version of the CogState computerized cognitive assessment battery may become a 
reliable tool for memory assessment in Taiwan. There are no simple screening tools available to 




function in cardiovascular clinics in Taiwan. Our findings suggest that the International 
Shopping List Task (ISLT) from the Chinese CogState may be a useful tool for clinical use. It 
correlated well with MoCA and significantly differentiated HF and non-HF groups (p< 0.001). 
Moreover, a recently western study also suggested that ISLT may be a reliable and brief 
screening tool because of its cross-cultural sensitivity, and ease of administration and scoring 
(Hammers, Jung, et al., 2012). Routine application of the ISLT in memory screening can help in 
early identification of memory deficits in HF patients.  
        In addition, older women with severe HF, more comorbidities and menopausal symptoms 
may be at the risk for memory decline. These women should be assessed their memory routinely 
in the clinics and evaluated if their self care abilities are compromised. 
                 Compensations and interventions: The type and severity of memory decline of 
women with HF were reported in this study. This is critical for health care professions to 
evaluate HF management and education program in acute or community settings such as 
outpatient clinics or community centers.  The information of aging, HF severity, chronic diseases, 
and menopausal symptoms on cognitive function should be included in these programs for 
reducing the risk of memory decline, such as healthy behaviors to minimize the occurrence of 
chronic diseases and self-care behaviors to avoid increasing the severity of HF.  
        In addition, verbal memory was the most affected memory domain in our sample. The 
educational program providing with visual or written materials would be helpful for HF patients 
to remember new information. Moreover, family members are often the primary caregivers for 
these women with HF in Taiwan society and involve most responsibilities of care. It is important 




        Using the knowledge of brain plasticity, Pressler et al. (2011) have demonstrated that a 
home-based nurse enhanced cognitive training intervention was feasible and had the potential to 
improve memory function for HF patients. Nurses may help enhance HF patients’ brain plasticity 
and maintain cognitive function by incorporate these novel stimulating activities into existing 
patient care, such as the visual (e.g., games, books, paintings, nature scenery) and auditory (e.g., 
music, discussions) stimulating activities.  
Conclusion 
        In conclusion, in this sample, Taiwanese postmenopausal women with HF had poorer 
working memory, and episodic memory performance in comparison with age- and education-
matched healthy women. Age explained working memory; age, HF severity, comorbidity, and 
HF type explained verbal memory; age and comorbidity explained visual memory. Although 
postmenopausal symptoms associated with estrogen decline were not associated with any of 
these performances, results indicated that subscales for anxiety and sexual symptoms 
significantly predicted verbal and visual memory performance. In addition, results obtained from 
this study provided acceptable levels of validity and reliability for the Chinese CogState using a 
sample of women with HF in Taiwan.  By better understanding memory performance in women 
with HF, the healthcare provider can design and test interventions tailored to specific risk factors 




























Demographic and Clinical Data (English Version) 
Personal information 
1.Age     _______ 
2.Race:    1. Taiwanese   2.  From Mainland China    3 Hakka             
                   4. Aborigine     5. Other                   .  
3.Marital Status:  1. Married    2.  Not married    3. Divorced   4 Widowed      
                                  5. Separated       
4. What level of education have you completed?  
  1. Elementary school   2. Middle school,    3. High school,   
 4. Vocational school,    5. Bachelor’s,          6. Master’s,       7. Doctorate 
5.What is the actual number of years you have completed in school? ________________   
6.Employment status:  1. Employed,    2. Unemployed  
7.Your occupation: _______________     (If retired, write previous occupation)        
8.Do you live alone?  1.  Yes     2.  No 
9.Handedness:          1.  Right handed,    2. Left handed 
The health history 
10.Height ___________ cm   
11.Weight    _____      _  kg    
12.BMI  _______________                                                         
13.Blood Pressure                      mmHg   
14.Heart Rate                     /min 
15.Smoking history: 
      1. Current smoker (smoking within 1 month of this encounter)  
     2. Recent smoker (stopped smoking between 1 month and 1 year before this  
            encounter ) 
      3. Former smoker (stopped more than 1 year before this encounter) 
      4. Never smoked 
16.How often do you drink alcoholic beverages (beer, wine, or liquor)? 
      1.   Never  
      2.   1 or fewer alcoholic drinks per week 
      3.   7 or more alcoholic drinks per week 





The menstrual history: 
17. Age of when menstruation began?      _______________      
18.Number of pregnancy?    _______________         
19.Number of live?    _______________                                     
20.When did your menstrual periods stop? Age:_______________ 
a. Time since menopause: ___________month 
b. Did you periods stop because you went through menopause?    
 1. Yes    2. No 
c.   Did you have hysterectomy or ovariectomy? 
     1. Yes, date: ___________,  2. No 
d.  If  ”Yes”, which kind of surgery you have? 
     1. Surgery for uterine only 
     2. Surgery for one side of ovary or two side of ovary 
     3. Surgery for uterine and ovary 
e.   Do you take estrogen replacement therapy/hormones now?  
     1. Yes    2. No 
f.   If  ”Yes”, for how long? _______________ 
g.   If “No”, did you ever take estrogen replacement therapy?          
     1. Yes    2. No 
The chart review information for HF condition 
21.Date for HF diagnosis?                                . 
22.How long has the patient been diagnosed with heart failure ? _____          month 
23.Left ventricular ejection fraction (LVEF) ___________     Date:                               . 
24.NYHA class by cardiologist        I        II         III       IV, Date:                    .  
25.Devices:      CRT            ICD            Other:                                   .           
26.Prescribed HF medications use: 
      1. Digoxin    2. Diuretic    3. ACEI    4.  ARB   
      5. Beta-adrenegic blocking agent           6. Aldosterone antagonist   
27.Comorbidity: 
       1.  History of MI    2.  History of CABG         3. History of CAD 
      4.  Hypertension    5.  Diabetes mellitus          6. Cancer     
      7.  Chronic Obstructive Pulmonary Disease    
      8.  Moderate or severe renal disease 
      9.  Hyperthyroidism 
      10.  Others:                                  .          




Demographic and Clinical Data (Chinese Version) 
基本資料及臨床資料 
 
請在各項符合您個人的資料  “” 打,謝謝您的合作! 
基本資料 
1.您的年齡     _______ 
2.您的籍貫:    1. 本省籍   2.  外省籍    3 客家人    4. 原住民     5. 其它                    
3.您的婚姻狀態:  1. 已婚    2.  未婚    3. 離婚   4 喪偶     5. 分居   6.. 其它                    
4.您的教育程度?  
  1. 國小   2. 國中,    3. 高中(職 ),   
 4. 專科,    5. 大學          6. 碩士       7. 博士 
5.您實際在學校接受教育的時間為幾年? ________________   
6.您目前是否仍在工作?:  1. 是          2. 否  
7. 您的職業為  : _______________     (若您已退休, 請寫下您之前的職業)        
8.您是否獨居?      1. 是          2. 否  
9.您的慣用手:      1.  右手,    2. 左手 
健康史 
10.身高 ___________ 公分   
11.體重    _____      _  公斤    
12.身體質量指數(BMI)  _______________(由研究者計算)                                                         
13.血壓 #1                     mmHg; #2                     mmHg     
14.心跳                     /每分鐘 
15.抽菸史: 
      1. 目前抽菸者 (最近一個月內有抽菸)  
     2.  最近抽菸者 (未抽菸一個月以上,一年以內) 
      3. 之前抽菸者 (停止抽菸超過一年) 
      4. 從未抽菸者 
16.您的飲酒情形 (啤酒, 或含酒精飲料)? 
      1.   從未飲酒 
      2.   一星期飲酒一杯或少於一杯 
      3.   一星期飲酒七杯或多於七杯  
      4.  每次飲酒五杯或多於五杯  
停經情形: 
17.您於                      歲初經?      




19.您的子女數?  ? _______________                                                   
20.您的停經年齡? _______________歲 
a. 停經時間;                           月                      
                  b. 請問您是自然停經嗎?    1. 是          2. 否  
c.   請問您是否有接受過子宮切除或卵巢切除手術嗎?   
      1. 是, 日期:                       ,  2. 否 
d.  請問是何種手術? 
      1. 僅子宮切除 
      2. 一邊或雙邊卵巢切除手術 
      3. 子宮和卵巢切除皆切除 
e.   請問您現在是否有接受女性賀爾蒙治療?  
                       1. 是          2. 否  
                  f.   如果您現在有接受女性賀爾蒙治療,請問多久時間?  _______________年 
g.   如果您現在沒有接受女性賀爾蒙治療”, 請問您是否曾經接受女性賀爾蒙治療?        
     1. 是          2. 否 
 
 心臟疾病特性(以下由研究者查閱病歷資料填寫) 
21.罹患心臟衰竭時間:     ____          _    月,    (診斷日期:                            .)               
22.心臟衰竭被診斷的時間有多久 :              月 
23.左心室射出率 (LVEF) ___________%,     檢查日期:                               . 
24. NYHA疾病分級?        I        II         III       IV,      日期:                    .  
25.輔助裝置:      CRT            ICD            Other:                                   .         
26.心臟疾病使用藥物 (由研究者協助填寫): 
      1. Digoxin    2. Diuretic    3. ACEI    4.  ARB   
     5. Beta-adrenegic blocking agent           6. Aldosterone antagonist   
27.合併其它疾病 (研究者查閱病歷資料填寫, 可複選): 
1.  心肌梗塞病史          2. 冠狀動脈繞道手術              3.  冠狀動脈疾病 
4.  高血壓          5. 糖尿病              6.  癌症                7.  慢性阻塞性肺病疾病    
      8.  腎臟疾病      9.  甲狀腺亢進      10.  其它:                                  .         
28.心臟衰竭類型: 























Duke Activity Status Index (English Version) 
 
Now I am going to ask you about some activities that people do. Please tell me if you can do these 
things. The responses are: 
 
1 = Yes, with no difficulty 
2 = Yes, with some difficulty 
3 = No, I can’t do this 




1. Take care of yourself, that is, eating, dressing,   1 2 3 4 
bathing, and using the toilet? 
 
2. Walk indoors, such as around your house?   1 2 3 4 
 
3. Walk a block or two on level ground?    1 2 3 4 
 
4. Climb a flight of stairs or walk up a hill?    1 2 3 4 
 
5. Run a short distance?      1 2 3 4 
 
6. Do light work around the house like dusting or   1 2 3 4 
washing dishes? 
 
7. Do moderate work around the house like vacuuming, 1 2 3 4 
sweeping floors, carrying in groceries?  
 
8. Do heavy work around the house like scrubbing floors,  1 2 3 4 
or lifting or moving heavy furniture? 
 
9. Do yard work like raking leaves, weeding or    1 2 3 4 
pushing a power mower? 
 
10. Have sexual relations?      1 2 3 4 
 
11. Participate in moderate recreational activities, like golf,  1 2 3 4 
bowling, dancing, double tennis, or throwing baseball or 
football? 
 
12. Participate in strenuous sports like swimming, single  1 2 3 4 
tennis, football, and basketball or skiing? 
 








Duke Activity Status Index (Chinese Version) 
 
活動狀況指標 
 請就過去這段時間依您是否可以執行這些活動回答, 請勾選出最符合您執行時的情況: 
 0 為可以執行,沒有困難 ;                     2 為不能執行這些活動;    
1 為可以執行,有些困難  ;                3 我因其他原因並沒有做這些活動 











動    
1 在室內行走,  
例如在你的屋內走動? 
    
2 做一些輕度的家務, 
例如,擦拭家具或洗碗? 
    
3 照顧自我的日常生活,路如:吃
飯,穿衣,洗澡和上廁所? 












    
7 從事性交活動     
8 爬一層樓梯或走上一小段上
坡路 




























The Greene Climacteric Scale (English Version) 
 
Please indicate the extent to which you are bothered at the moment by any of these symptoms by 
placing a tick in the appropriate box. 
 
 Symptoms Not at all A 
little 
Quite a bit Extremely Score 0-3 
1 Heart beating quickly or 
strongly 
     
2 Feeling  tense or nervous      
3 Difficulty in sleeping      
4 Excitable      
5 Attacks of panic      
6 Difficulty in concentrating      
7 Fleeing tired or lacking in 
energy 
     
8 Loss of interest in most things      
9 Feeling unhappy or depressed      
10 Crying spells      
11 Irritability      
12 Feeling dizzy or faint      
13 Pressure or tightness in head or 
body 
     
14 Parts of body feel numb or 
tingling 
     
15 Headaches      
16 Muscle and joint paints      
17 Loss of feeling in hands or feet      
18 Breathing difficulties      
19 Hot flushes/sudden warmth      
20 Sweating night or day      
21 Loss of interest in sex      
22 cold sweats (night or day)      
23 waking up during the night      
24 vaginal dryness      
25 forgetfulness      
26 backache      
 
     P (1-11)=         A (1-6)=            S (12-18)=            D(7-11)=            V(19-20)=             S (21)= 
 














經常        
2分 
嚴重       
3分 
Score 0-3 
1 心跳好快      
2 覺得有壓力,神經質      
3 失眠,睡得不好      
4 興奮      
5 不安感      
6 注意力不集中      
7 覺得累,沒力氣      
8 對很多事情沒興趣      
9 不快樂,鬱悶      
10 常想哭      
11 煩躁      
12 覺得頭暈      
13 覺得頭和身體很重      
14 有時身體的某部分會沒感覺或刺
痛 
     
15 頭痛      
16 肌肉,關節痛      
17 有時手腳會沒感覺或麻麻的      
18 呼吸不順或困難      
19 熱潮紅(臉好熱)      
20 白天或夜間盜汗(白天或晚上常
冒汗) 
     
21 性慾降低      
22 白天或夜間冒冷汗      
23 夜間醒來      
24 陰道乾燥      
25 健忘      







Scripts for CogState (English Version)              
 
Detection task: Has the card turned over? 
Say: In the task, a playing card will appear in the center of the screen. Press the YES button 
when the card turns face-up as fast as you can. If you make a mistake you will hear an error 
sound. This means you have responded too soon. Try to make your responses as acute and fast as 
possible after a card turns face-up. Are you ready to start? Press ENTER to begin. 
 
Identification Task: is the card red? 
Say: In the task, a playing card will appear in the center of the screen. As soon as it turns face-up, 
you must decide: is the color of the card red? If it is red, press the YES button. If it is not red, 
press the NO BUTTON. If you make a mistake you will hear an error sound. Try to make your 
responses as accurate and fast as possible after a card turns face-up. Are you ready to start? Press 
ENTER to begin. 
 
One Back Task: is the previous card the same? 
Say: In the task, a playing card will appear in the center of the screen. As soon as it turns face-up 
you must decide: is the card exactly the same as the previous card? If it is exactly the same as the 
previous card,press the YES button. If it is not exactly the same as the previous card, press the 
NO button. If you make a mistake you will hear an error sound. Try to make your responses as 
accurate and fast as possible after the card turns face-up.  Press ENTER to begin. 
 
International Shopping List Task 
Say: the task should start with the screen facing the supervisor so that the subject cannot see the 
screen. Read the following instructions out loud to them. In this task, I am going to read you a 
shopping list. I would like you to remember as many as items from this list as possible. Are you 
ready to start? Press ENTER to begin. 
 
International Shopping List Task - Delayed Recall  
Say: In this task, now we are going to go back to the shopping list I read to you earlier. I need 
you to try and remember the items on this list and tell me what they were. Are you ready to start? 
Then, press ENTER to begin. “Tell me as many of the items on the shopping list as you can 
remember?” 
 
One Card Learning Task: have you seen this card before in this task? 
Say: In this task, a playing card will appear face-down in the center of the screen and then turn 
face-up. As soon as a card turns face-up decide if you have seen it before in this task. Only a few 
of the face-up cards will repeat during the task. Cards seen in the practice are not used again. If 
you have seen the card before in this task, press the YES button. If you have not seen the card 
before in this task, press the NO button. If you make a mistake you will hear an error sound. Try 
to make your responses as accurate and fast as possible after the card turns face-up. Press 
ENTER to begin. 
 




Say: now the pictures will be presented in the center of the screen, and you must tap on the 
peripheral location where that picture previously appeared. Begin by tapping the target on the 





Scripts for CogState (Chinese Version)          
電腦測驗說明     
 




快而準確的回答,你準備好了嗎? 請按下 Enter鍵開始 
 
Identification Task: is the card red? 
識別任務: 卡片是紅色的嗎? 
在此項任務中,螢幕中央將顯是一張遊戲卡,請在卡片翻轉後以最快的速度確定: 
卡片顏色是否為紅色? 如果卡片顏色為紅色, 請按下按鈕’是”, 如果卡片顏色不是紅色, 
請按下按鈕’否”, 如果回答錯誤,你將聽到一聲錯誤提示音, 
請你在卡片翻轉後盡量快而準確的回答,你準備好了嗎? 請按下 Enter鍵開始 
 






請你在卡片翻轉後盡量快而準確的回答,你準備好了嗎? 請按下 Enter鍵開始 
 
International Shopping List Task 
此項任務開始前,應使評測對象背對螢幕以免其看到螢幕內容,同事向其大聲讀出以下說明, 
在此項任務中, 我將向你讀出一份購物清單,希望你能盡量記住清單中的項目, 
你準備好了嗎? 請按下 Enter鍵開始 
 
International Shopping List Task - Delayed Recall  
在此項任務中, 我們要回到我之前將你讀出的購物清單, 
我需要你試著回憶清單中的項目並告訴我, 你準備好了嗎? 請按下 Enter鍵開始, 
請盡量告訴我你所記得的購物清單項目. 
 





請按下按鈕’是”, 如果你未曾在在此項任務中見過面前的卡片, 請按下按鈕’否”, 
如果回答錯誤,你將聽到一聲錯誤提示音, 





Continuous Paired Associate Learning Task: in what locations do these pictures belong? 
連續配對關聯默記任務: 這些圖片屬於哪些位置? 
現在這些圖片將顯示於螢幕的中央,請你點觸上一次顯示圖片得周邊位置,首先點觸位於中















































 Informed Consent (English Version) 
 
Consent to Participate in a Research Study 
 
Memory Performance in Taiwanese Postmenopausal Women with Heart Failure 
 
Invitation to participate in a research study 
Cheng-Chen Chou, PhD(c), a student at the University of Michigan in the School of Nursing, 
invites you be part of a research project that she will conduct in order to complete requirements 
for an advanced degree.  She is supervised by Dr. Susan Pressler, Ph.D.  The purpose of the 
study is to learn more about memory change in Taiwanese postmenopausal women with HF (HF 
group) and without HF (healthy women group), and the possible influencing factors. Heart 
failure can decrease the blood flow in our body, including the brain, which may affect memory. 
Women who are postmenopausal may also experience memory problems because of estrogen 
decline. The knowledge will provide a scientific base to develop effective nursing intervention.  
We are asking you to participate because you recently attended an outpatient clinic of the 
cardiology, gynecology, or women’s health clinic or you are the worker or family member of 
patents in Tri-service General Hospital, Taipei, Taiwan. 
 
Description of your involvement  
 
Healthy an HF groups: 
The participation includes one face-to-face interview for both group and chart review for only 
the HF group. If you agree to be part of the research study, the investigator will fully explain the 
study including purpose, benefits, risk, and procedures.  After the informed consent is signed you 
will be asked to participate in one face-to-face interview in a quiet room at Tri-service General 
Hospital, Taipei.  
The interview should take about one hour; you will be asked your background, height, weight, 
activity level, menopausal symptoms. You will have your blood pressure checked. The 
investigator will bring the computer and explain how to complete the memory testing. You will 
complete the computer testing around 20 minutes to look at your memory and thinking.  
 
HF group only: 
In addition, for the heart failure group, we will obtain information about your HF condition from 
the medical records from your physician in the clinic by using a checklist. The information we 
ask from medical records includes: date of HF diagnosis, echocardiography result (left 
ventricular ejection fraction), and New York Heart Association class, type of HF, devices, HF 
medicines, and comorbid conditions.  
 
Benefits  
While you may not receive a direct benefit from participating in this research, some people find 
it helpful to discuss their health with a nurse (the investigator) and to learn how to use the 
computer. We hope that this study will contribute to the improvement of memory for 





Risks and discomforts  
The researchers have taken steps to minimize the risks of this study.  Even so, you may still have 
problems or side effects related to your participation, even when the researchers are careful to 
avoid them.  These risks may include the following: 1) possible frustration or becoming upset 
with the computer testing; and 2) possible loss of confidentiality. We will minimize these risks 
by making sure you are comfortable and ready to have the computer testing and keeping the files 
in a locked cabinet in a locked room that is only available for the investigators.  
 
Compensation 
You will be paid a $10 (NT300) Carrefour gift card for participating in the entire interview 
session. You will not receive the incentive if you do not complete the study. You will need to 
pay for your own travel and parking expenses.  
 
Confidentiality 
We plan to publish the results of this study and your data will be kept for 6 years after the study 
is completed, but will not include any information that would identify you. We will plan and 
prepare publications of our results.  To keep your information safe, the research records will be 
placed in a locked file cabinet in a locked room. The researchers will enter study data on a 
computer that is password-protected and uses special coding to protect the information.  To 
protect confidentiality, your real name will not be used in the written copy of the discussion.   
 
Signing this form gives the researchers your permission to obtain, use, and share information 
about you for this study, and is required in order for you to take part in the study.   
 
There are some reasons why people other than the researchers may need to see information you 
provided as part of the study.  This includes organizations responsible for making sure the 
research is done safely and properly, including the University of Michigan and other government 
officials.   
 
Voluntary nature of the study  
Participating in this study is completely voluntary. The participation in the research does not 
include medical treatment for any healthcare condition. You can skip any question you want to 
skip.  Even if you decide to participate now, you may change your mind and stop at any time. If 
you leave the study before it is finished, there will be no penalty to you. You will not lose any 
benefits to which you may otherwise be entitled.  If you choose to tell the researchers why you 
are leaving the study, your reasons for leaving may be kept as part of the study record. 
 
 
Contact information  
If you have questions about this research, including questions about the scheduling of the 
interview or your payment for participating, you can contact the investigator: Cheng-Chen Chou, 
PhD (c), University of Michigan, School of Nursing, 400 N. Ingalls, MI 48109, Telephone: 
0966-827-278 (Taiwan),  chenchou@umich.edu.  You can also contact her faculty advisor, 
Susan Pressler, Ph.D., University of Michigan, School of Nursing, 400 N. Ingalls, Room 2180, 





If you have any questions about your rights as a research participant, please contact the 
University of Michigan Institutional Review Board Health Sciences and Behavioral Sciences, 
(734) 936-0933, 540 E. Liberty St., Suite 202 Ann Arbor, MI 48104-2210, irbhsbs@umich.edu. 
 
Consent 
By signing this document, you are agreeing to be in the study.  You will be given a copy of this 
document for your records and one copy will be kept with the study records.  Be sure that 
questions you have about the study have been answered and that you understand what you are 
being asked to do.  You may contact the researcher if you think of a question later. 
 
I agree to participate in the study.  
 
_____________________________________  ____________________ 





Authorization for medical records information release (HF group only) 
 
I hereby authorize                                                  to receive information from the medical records 
by using a checklist for the purpose of participation in this study. The records to be released are: 
date for HF diagnosis, echocardiography result (left ventricular ejection fraction), New York 
Heart Association class, type of HF, devices, HF medicines, and comorbid conditions.    
 
Information will not be released without a valid signature below. I can cancel this authorization 
at any time. 
  
I agree the person mentioned above to receive medical records information as described above.  
 
_____________________________________  ____________________ 
























密西根大學護理學院博士班研究生周承珍邀請您成為她的研究計劃的個案。  她由 Susan  









心臟衰竭婦女組與一般婦女組 (兩組)  
您的參與包括面對面資料收集(兩組皆要)和病歷資料收集(僅心臟衰竭婦女組),如果您同
意參與此研究，我們會與您約在三軍總醫院的房間進行資料收集。          
資料收集約一個小時左右。  我們會解釋包括目的、 利益、 可能的風險和過程的研究。 















，您仍可能出現參與研究有關的問題或副作用。  這些可能風險包括下列: 1) 



































人，電話： 0966-827-278 (台灣手機), 電子信箱: 
chenchou@umich.edu。 您也可以聯繫她的指導教授 Susan Pressler博士,美國 




行為科學人體審查委員會，電話：002-1-734- 9360933，地址: 540 E. Liberty St., Suite 













本研究中做記錄。  請確認您提出研究有關的問題已獲答覆並瞭解什麼是您需要做的。  
如果您之後仍有問題，歡迎您聯繫本研究人員。 
  
我同意參與這項研究。   
 
 











我同意                                      因為研究的目的可以從我的病歷上資料獲得以下資訊:  
心臟衰竭的時間,左心室心射出率, 







簽名 ______________________________             __日期__________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
